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Recent molecular studies have revealed that the canine gastrointestinal tract 
(GIT) harbors a highly complex microbial ecosystem. Gut microbes play a very 
important role in the development and regulation of the immune system of the host, 
mediated in-part through the production of immunomodulatory metabolites (e.g., 
butyrate, propionate, indole). Limited information is available about potential changes in 
the predominant bacterial groups in dogs with acute diarrhea, and characterizing the 
functional gene content of the microbiome may help to understand relationships between 
microbiota, endogenous metabolites, and gastrointestinal disease. Therefore, the aim of 
this study was (1) to characterize the fecal microbiome in healthy dogs, dogs with acute 
non-hemorrhagic diarrhea (NHD), and dogs with acute hemorrhagic diarrhea (AHD) 
using 16S rRNA gene sequencing and qPCR analysis; (2) to measure fecal 
concentrations of short-chain fatty acids (SCFAs) and branched-chain fatty acids 
(BCFAs); and (3) to describe the functional gene content of the fecal microbiome. 
Fecal samples were collected from healthy dogs (n=13), dogs with NHD (n=5), 
and dogs with AHD (n=6). The fecal microbiota were analyzed by 454-pyrosequencing 
of 16S rRNA genes and qPCR assays. SCFAs were quantified by gas 
chromatography/mass spectrometry (GC/MS). Functional genes present in the 
microbiome were predicted from the 16S rRNA gene data using the software PICRUSt. 
The Shannon Index for bacterial diversity was significantly decreased in dogs 
with acute diarrhea (AD; both NHD and AHD groups combined) compared to healthy 
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dogs (p=0.0020). Sequences belonging to Bacteroidetes were significantly decreased in 
dogs with AD compared to healthy dogs (p=0.0280). Sequences belonging to the genus 
Faecalibacterium and an unclassified genus within the family Ruminococcaceae were 
both significantly decreased in dogs with AD compared to healthy dogs (p=0.0319 and 
0.0368, respectively). Also, a significant decrease in Blautia spp. were observed in dogs 
with AD compared to healthy dogs (p=0.0472). The proportions of butyric acid were 
significantly increased and proportions of propionic acid were significantly decreased in 
dogs with AD compared to healthy dogs (p<0.05 for both). Significant differences were 
not observed in functional categories among all dogs after adjustment for multiple 
comparisons. 
Results of this study revealed a bacterial dysbiosis in fecal samples of dogs with 
NHD and dogs with AHD compared to healthy dogs. The bacterial groups that were 
commonly decreased during acute diarrhea are considered to be important SCFA 
producers and may be important for canine intestinal health. Future studies to evaluate 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
MICROBIOTA IN GASTROINTESTINAL HEALTH AND IMMUNITY 
It is estimated that the human intestinal tract contains up to 100 trillion microbes. 
The entire gene content of this collection of microbes is referred to as the intestinal 
microbiome, and it is thought to contain 100 times more genes than the human genome 
[1,2]. Also, the canine gastrointestinal tract harbors a complex and highly diverse 
assembly of bacteria [3-5]. Given this complex and intrinsic bacterial population, it is 
not surprising that there is an inherent relationship between host and resident microbiota 
that is important for gastrointestinal health [6]. Gastrointestinal microbes stimulate the 
gastrointestinal immune system and the postnatal development of gut structure. 
Furthermore, microbes aid in defending against invading pathogens and produce various 
metabolites (e.g., short-chain fatty acids (SCFAs), vitamins) that can be utilized by the 
host [7]. The intestinal microbiota also plays a crucial role in intestinal immunity. For 
example, intestinal bacteria are recognized by toll-like receptors (TLRs), and these TLRs 
play a key role in the innate defense by communicating with the immune system to 
activate adaptive lymphoid tissue [8]. Studies of the gastrointestinal microbiota in germ-
free animals have revealed insight into the development of host phenotype [9].  The 
gastrointestinal tract can be highly dynamic and must readily adapt, especially during the  
neonatal period [9]. In the neonate, physiological microbial colonization of the 
gastrointestinal tract is believed to advance critical systems responsible for humoral and 
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cellular mucosal immunity as well as normal host physiology [9]. This is evident from 
studies involving germ-free rodent models. These germ-free animals, by definition born 
and raised with a total lack of the intestinal microbiota, typically require an increased 
energy intake and have lower serum concentrations of vitamins B and K [9,10]. 
Furthermore, they have an altered intestinal structure and morphology and display 
delayed gastric motility compared to conventionally raised animals [10,11]. 
Given the importance of intestinal microbes for gastrointestinal health, studies 
have evaluated various factors that influence the composition and activity of the 
gastrointestinal microbiota. Of particular interest is the effect of various diets on fecal 
bacterial populations. One study evaluated the effects of a high-fiber diet (10% total 
fiber; 5% soybean hulls and 5% beet pulp) compared to a control diet low in fiber on the 
fecal microbiota of healthy dogs [12]. No significant changes in fecal concentrations of 
various microbial metabolites (e.g., ammonia, sulfide, and indole) were observed in the 
dogs fed the 10% high-fiber diet [12]. In contrast, feeding the high-fiber diet led to 
significant increases in fecal concentrations of the SCFAs acetate, propionate, and 
butyrate compared to the low-fiber diet. However, no changes in fecal microbial 
populations were observed in dogs fed the high-fiber diet compared to those in dogs fed 
the low-fiber control diet [12]. A separate study compared the effects of three different 
diets: a high-carbohydrate diet (starch concentration: 438 g/kg), a high-protein diet 
(crude protein concentration: 609 g/kg), and a standard commercial dry diet (starch and 
crude protein concentration: 277 g/kg and 264 g/kg; respectively) on the colonic 
microbiota of healthy Beagle dogs [13]. The fecal microbiota in dogs fed the dry 
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commercial diet generally harbored increased bacterial abundances of Clostridiales, 
Lactobacillales, Coriobacteriales, and Bacteroidales. Sequences belonging to 
Clostridiales were the most common bacterial order in fecal samples from dogs fed the 
dry commercial diet and high-carbohydrate diet. Overall, the proportion of Clostridiales 
in dogs fed the high-protein diet was significantly decreased compared to dogs fed the 
dry commercial diet.  Lactobacillales and Bacteroidales were not detected in fecal 
samples from dogs fed the high-carbohydrate and high-protein diets [13]. These studies 
show that the fecal microbiota of dogs can be altered by changes in the diet.  
 
CHARACTERIZATION OF THE INTESTINAL MICROBIOTA 
Bacteria are the most predominant microbes present in the GI tract of mammals, 
comprising approximately >98% of microbial cells [14]. In the past, studies have 
focused primarily on cultivation methods to characterize the bacterial groups present in 
the GI tract. Studies in humans and dogs reported that the predominant culturable 
bacterial groups in the GI tract were Lactobacillus, Bifidobacterium, Eubacterium, 
Bacteroides, and Peptostreptococcus spp. [15,16]. Cultivation techniques, however, may 
not provide a complete picture of the gastrointestinal microbiota; the GI tract harbors 
many anaerobic bacteria, which are subject to degradation during sample handling. 
Therefore, these anaerobes are often poorly represented in the results of cultivation 
studies [17-19]. Because bacterial culture underestimates microbial diversity, molecular 
tools typically targeting the 16S ribosomal ribonucleic acid (rRNA) gene, are now being 
commonly utilized and allow to characterize a more complete profile of the 
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gastrointestinal microbiota [19-22]. In one study, the bacterial phyla Firmicutes (47.7%), 
Proteobacteria (23.3%), Fusobacteria (16.6%), and Bacteroidetes (12.4%) were the 
major bacterial groups identified in intestinal content collected from the duodenum, 
jejunum, ileum, and colon of six healthy dogs [23]. Other bacterial phyla such as 
Spirochaetes, Tenericutes, Verrucomicrobia, TM7, Cyanobacteria, Chloroflexi, 
Planctomycetes, and some unclassified bacterial lineages generally make up lesser 
proportions (< 1%) of bacteria throughout the gastrointestinal (GI) tract in healthy dogs 
[24]. DNA sequence analysis of the human fecal microbiota has revealed somewhat 
similar bacterial proportions, with Firmicutes (81.2%), Actinobacteria (14.6%), 
Bacteroidetes (2.5%), and Proteobacteria (1.7%), representing the highest percentage of 
sequence reads in one study [25]. Similarly, based on one study, the fecal microbiota of 
mice is dominated by Firmicutes (56.2%), Bacteroidetes (24.4%), Actinobacteria 
(15.5%), and Proteobacteria (3.0%) [26]. 
Culture-based methods. There are inherent limitations to cultivation techniques 
when attempting to characterize complex microbial ecosystems such as the ones residing 
in the GI tract of mammals [27]. Some authors have suggested that more than 99% of all 
environmental prokaryotes are uncultivable [27], and studies estimate that only 10-50% 
of bacteria that are part of the gastrointestinal microbiota can be cultured 
[14,17,22,27,28]. Limitations of bacterial culture include a lack of optimal growth 
conditions for the majority of gastrointestinal microorganisms and the need for anaerobic 
handling of isolated bacteria [22]. Mutualistic interactions between the various 
microorganisms and/or the host that are required for optimal growth of bacteria can often 
 5 
 
not be well replicated in vitro [29]. Lastly, classification of bacterial species based on 
phenotypic (e.g., assessment of the morphology of isolated colonies) is often inaccurate, 
and many cultured isolates require molecular typing for accurate identification of 
isolates [20,30]. 
Molecular-based methods. Since bacterial culture largely underestimates the 
microbial diversity in the GI tract, molecular approaches are now commonly being used 
to characterize gut microbial ecology. Molecular tools require DNA or RNA to be 
extracted from biological samples (e.g., feces, biopsy specimens, or luminal content). 
Specific genes (e.g., the 16S rRNA gene) are then amplified using universal bacterial 
primers and the diversity of the bacterial populations are evaluated using phylogenetic 
methods such as DNA sequencing. Molecular-based methods allow demonstration of  
evolutionary relationships between bacterial communities and between samples, while 
identifying the presence and abundance of bacteria in a given sample [31].  
While molecular-based methods are currently more frequently employed for the 
characterization of bacterial communities, the techniques involved in 16S rRNA gene 
sequencing are not new. In 1977 Sanger et al. developed a sequencing method, which 
utilized chain-terminating inhibitors of DNA polymerase and was the most rapid and 
accurate method at the time [32]. This method was, however, costly and initial studies 
characterizing the gut microbiota using clone libraries were limited to a few hundred 
sequences per sample [33]. Over time, there have been vast improvements for robustness 
and cost-effectiveness in 16S rRNA gene sequencing [32]. For example, 454-
pyrosequencing is an automated high-throughput sequencing platform that is capable of 
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sequencing several thousand PCR amplicons within a few hours [29]. Newer platforms 
in sequencing such as Illumina and Ion-Torrent have recently been introduced and are 
even more-cost effective than 454-pyrosequencing [34]. Since the development of high-
throughput methods, similar advances in processing of the large amounts of sequencing 
data generated by these automated platforms have become necessary. Open-source 
software tools such as QIIME which stands for Quantitative Insights into Microbial 
Ecology are now available [35]. QIIME allows phylogenetic analysis of 16S rRNA gene 
sequences and provides an analysis pipeline that reaches from the raw sequencing output 
created by the sequencing machine through bacterial taxonomy assignment, statistical 
analysis, and graphical visualization of microbial communities [35]. 
For the purposes of this introduction, quantitative PCR and pyrosequencing 
reaction methodologies are outlined to describe the primary tools that were utilized in 
this research project: 
Polymerase Chain Reaction (PCR). Conventional PCR relies upon 
electrophoresis-based visualization of target amplicons at the end of the assay after all 
amplification cycles have been performed. In contrast, quantitative real-time PCR 
(qPCR) monitors the progress of the amplification reaction as it occurs in real time. With 
qPCR, a larger amount of starting material (DNA or cDNA) is directly proportional to 
fluorescence emission [36]. Cyanine dye (e.g., SYBR® Green I) and hydrolysis probe 




SYBR® Green I is a dye that binds to double stranded DNA and the fluorescence 
signal increases proportional to the generation of double stranded PCR product [37]. 
SYBR® Green I dye chemistry does not require a probe, and is more cost effective 
compared to hydrolysis probe based assays. This method however, can generate false 
positive signals, as SYBR® Green I dye indiscriminately binds to any double stranded 
DNA present in a reaction tube, including primer dimers and also non-specific 
amplification products [38]. 
DNA and cDNA can also be quantified by TaqMan® chemistry [37]. In a 
TaqMan® assay, an oligonucleotide probe is designed containing a reporter fluorescent 
dye (e.g., 6-carboxyfluorescein [FAM] or tetrachlorofluorescein [TET]) on the 5’ end 
and a quencher dye (e.g., tetramethylrhodamine [TAMRA]) on the 3’ end of the probe. 
The quencher dye acts to reduce the fluorescence emitted by the reporter dye when in 
solution. If the target sequence is present, the probe anneals downstream of the primer 
and is subsequently cleaved by the 5’ nuclease activity of Taq DNA polymerase after 
extension of the primer. Once the probe is cleaved, the reporter dye is released and 
separated from the quencher dye resulting in a measurable increase in fluorescence 
signal. TaqMan® chemistry is highly specific for the target sequence; it is also possible 
to target two distinct sequence targets in one reaction tube if different reporter dyes are 
used. A limitation of TaqMan® chemistry is that different probes must be synthesized for 
different sequences in addition to forward and reverse primers, which makes these 
assays more expensive than SYBR® Green assays [39,40]. 
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Pyrosequencing reaction. First, an amplicon is generated by PCR that contains a 
biotinylated 5’ terminus. After linking biotinylated double-stranded DNA, amplicons are 
then linked to a solid surface coated with streptavidin and denatured. During DNA 
synthesis and successful incorporation of nucleotides, inorganic pyrophosphate (PPi) is 
consequentially generated and detected by a camera and visualized on a computer, then 
translated into nucleotide bases. 
Biochemically, a nucleic acid polymerization reaction takes place, which leads to 
the release of PPi that is then incorporated into adenosine triphosphate (ATP) by ATP 
sulfurylase. Generated ATP is then detected by luciferase-producing photons. Luciferase 
in turn oxidizes luciferin, generating light. Any unused ATP and deoxynucleotide is then 
degraded by the nucleotide-degrading enzyme apyrase to reduce interference during PPi 
detection. In a traditional pyrosequencing machine, an inkjet cartridge is used to 
distribute enzymes, substrates, and all sequential nucleotides into the wells of a 
microtiter plate. The plate undergoes continuous agitation to increase reaction efficiency 
[41]. A lens array is used for detecting fluorescence from each well projected onto the 
chip of a camera. 
Limitations of molecular methods. While molecular methods are becoming 
widely used, it is important to recognize that these methods also have limitations. 
Different cell lysis procedures during DNA extraction can introduce inter-assay 
variability (e.g., bead beating vs. heating of lysis buffer) [24,42]. Another limitation is 
that 16S rRNA gene copies cannot be directly converted into cell counts because some 
bacteria can have multiple numbers of rRNA operons [5]. Operons can vary from 1 to 15 
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within each individual bacterial phylotype and are subject to change throughout cell 
growth and metabolic activity. Therefore, the abundance of bacterial groups with higher 
operon counts may be more likely to be falsely overestimated [43]. 
 
THE CANINE INTESTINAL MICROBIOTA 
The gastrointestinal tract of dogs is inhabited by a diverse and complex 
microbiota; our understanding of the composition and dynamics of it is very basic but 
growing [42]. In one study, bacterial abundances were investigated in various regions of 
the GI tract of nine healthy male Beagle dogs [16]. The highest number of bacteria 
cultured was 1010 colony-forming units (CFU) per gram of tissue and colonic content. 
Throughout the GIT the most abundant genera were Bacteroides, Bifidobacterium, 
Peptostreptococcus, Eubacterium, Clostridium, and Peptococcus. Streptococcus 
represented the highest number of facultative anaerobes. Microscopic counting of 
bacterial cell suspensions using  a Petroff-Hausser (PH) chamber revealed that cecal and 
ileal compartments harbor about one to three less logs of CFUs per gram of tissue and 
contents than in the colon [16]. 
One study reported bacterial abundances in the jejunal content and feces from 
twenty-two Beagle dogs [44]. In this study, small intestinal fluid samples as well as 
naturally passed feces were analyzed [44]. The microbiota of seven of these dogs was 
evaluated at weekly time intervals over a four week period [44].  Aerobic and facultative 
anaerobic bacteria on one side and anaerobic bacteria on the other were found with equal 
abundance in jejunal samples, while anaerobic bacteria were significantly more abundant 
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in fecal samples [44]. While total bacterial numbers were significantly less abundant in 
the jejunum than in the feces (range: 102 to 106 CFU/g vs. 108 to 1011 CFU/g, 
respectively), some bacterial groups were more abundant in the proximal small intestine 
compared to feces [44]. Staphylococcus and non-fermentative gram-negative rods were 
found in greater proportions in the proximal small intestine than in the feces (64% versus 
36% and 27% versus 9% of all bacterial organisms, respectively) [44]. Bile-resistant 
Bacteroides spp., Clostridium hiranonis-like organisms, and Lactobacillus spp. were 
highly abundant in fecal samples [44]. The microbiota in the small intestine was much 
less diverse and showed significant fluctuations over time compared to the fecal 
microbiota which remained stable over time [44]. These results show that the microbiota 
is highly diverse throughout the gastrointestinal tract [44]. 
One study used 16S rRNA gene sequencing to characterize the fecal bacterial 
and fungal communities in 12 healthy dogs and 12 healthy cats using bacterial and 
fungal tag-encoded FLX-Titanium pyrosequencing [4]. Additionally, group-specific 16S 
rRNA gene clone libraries for Bifidobacterium spp. and Lactobacillus spp. were 
constructed. The results showed that the most prevalent bacterial phyla in the feces of 
dogs were Firmicutes and Bacteroidetes [4]. Furthermore, the most prevalent bacterial 
class in the feces of dogs was Clostridia, mostly comprised of the genera Clostridium 
(clusters XIVa and XI) and Ruminococcus [4].   
454 FLX high-throughput pyrosequencing was used to analyze the fecal 
microbiota of eleven healthy adult miniature Schnauzer dogs in one study [45]. The dogs 
were of mixed sex and age and some shared common genetic lineages. They were all 
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housed on the same premises and had relatively controlled exercise and feeding habits. 
Fusobacterium (40%), Bacteroidetes (33%), Proteobacteria (11%), and Actinobacteria 
(<1%) were found to be the predominant phyla in the fecal microbiota. Individual dogs 
showed a high variability in the abundance of bacterial genera in their fecal samples  
[45]. Alpha-diversity measures for species richness (e.g., Chao 1 metric; a predictive 
measure) showed that fecal microbiota may harbor as many as 500 to 1,500 
observational taxonomic units (OTUs) [45]. 
Another study investigated the bacterial diversity in the lumen of the canine 
duodenum, jejunum, ileum, and colon by direct sequence analysis of the 16S rRNA gene 
[23]. Intestinal contents were collected from six healthy unrelated Hound dogs; 
immediately after euthanasia the abdominal cavity was opened and the intestines were 
isolated. Sequences belonging to Clostridiales were most abundant in the duodenum 
(40%) and jejunum (39%). Sequences belonging to Clostridium (clusters XIVa and XI) 
were the predominant groups in the proximal small intestine and colon. Fusobacteriales 
was the most abundant order found in the ileum (33%), while Bacteroidales was the 
most abundant order found in the colon (30%). The order Enterobacteriales was more 
abundant in the small intestine than in the colon, and Lactobacillales occurred 






THE ROLE OF THE INTESTINAL MICROBIOTA IN CANINE 
GASTROINTESTINAL DISEASE 
 A fecal dysbiosis has been reported in dogs with clinical signs of GI disease [46]. 
Furthermore, studies have indicated that the microbiota is actually needed for the 
spontaneous development of intestinal inflammation. Studies in mice with targeted 
deletion of the gene coding for anti-inflammatory cytokine IL-10 were used to test the 
hypothesis that enteric bacteria are necessary for the development of spontaneous colitis 
and immune system activation [47]. IL-10-deficient (IL-10-/-) mice develop 
inflammation of the intestine with a resident microbial population, which can be abated 
by the application of IL-10 [48]. Mice that are IL-10-/- and kept under germ-free 
conditions do not develop enterocolitis, suggesting that a resident microbial community 
is necessary for a GI response in IL-10 deficient mice [47-52].  
One study investigated the predominant fecal microbiota of dogs with chronic 
diarrhea by fluorescence in situ hybridization (FISH) and Denaturing Gradient Gel 
Electrophoresis (DGGE) and examined the effects of a fiber blend on the canine fecal 
microbiota [53]. Dogs with chronic diarrhea (n=9) and healthy control dogs (n=8) were 
fed a high-fiber regimen (i.e., psyllium, which is a fermentable fiber) for three weeks 
[53]. Dogs with chronic diarrhea and healthy control dogs shared the Atopobium cluster, 
the Lactobacillus-Enterococcus group, and the Clostridium cluster XIV as predominant 
bacterial groups [53]. Dogs with chronic diarrhea had a significantly increased cell count 
of Bacteroides at baseline and significantly decreased cell counts of Atopobium cluster 
cells following fiber supplementation compared to healthy control dogs [53]. The 
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abundance of Atopobium cluster increased significantly in healthy control dogs, while 
cell counts of sulphate-reducing bacteria decreased significantly. Also, Clostridium 
clusters I and II cell counts increased significantly in dogs with chronic diarrhea during 
fiber supplementation [53]. 
 To further characterize the bacterial microbiota in dogs with various 
gastrointestinal disorders, one study analyzed fecal samples from healthy dogs (n=32), 
dogs with acute non-hemorrhagic diarrhea (n=12), dogs with acute hemorrhagic diarrhea 
(n=13), and dogs with active IBD (n=9), and therapeutically controlled idiopathic IBD 
(n=10) [54]. Analysis was performed by 454-pyrosequencing and qPCR assays of the 
16S rRNA gene. Bacterial communities of dogs with acute hemorrhagic diarrhea and 
acute non-hemorrhagic diarrhea were notably different than those of healthy dogs 
(Analysis of Similarity (ANOSIM): p=0.001 and p=0.003; respectively) as observed by 
principle coordinate analysis (PCoA) plots based on unweighted UniFrac distances [54]. 
Blautia spp. and Ruminococcaceae, including the genera Faecalibacterium and 
Turicibacter, were significantly decreased in dogs with acute hemorrhagic diarrhea [54]. 
Members of the genus Sutterella and Clostridium perfringens were significantly 
increased in dogs with acute hemorrhagic diarrhea compared to healthy dogs. Microbial 
communities between healthy dogs and dogs with IBD were not significantly different as 
observed on PCoA plots. Faecalibacterium spp. and Fusobacteria decreased 
significantly in dogs with clinically active IBD; during remission, however, their 
abundances increased [54]. Also, short-chain fatty acid producing bacteria (e.g., 
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Erysipelotrichaceae, Ruminococcaceae, and Lachnospiraceae) were significantly 
decreased in dogs with acute diarrhea [54]. 
 Lastly, another study utilized qPCR based on the 16s rRNA gene. Feces in 
healthy dogs (n = 242), dogs with chronic enteropathies (CE) (n = 118), and dogs with 
acute hemorrhagic diarrhea (AHD) (n = 57) were evaluated [46]. There were marked 
differences in bacterial abundances between healthy dogs, dogs with CE, and dogs with 
AHD. Abundances of Faecalibacterium spp., Turicibacter spp., and Ruminococcaceae 
were significantly decreased in dogs with CE and AHD compared to healthy dogs. 
Lactobacillus spp. and Streptococcus spp. were significantly increased in dogs with CE. 
Abundances of Clostridium perfringens and E. coli were significantly increased in dogs 
with AHD compared to healthy dogs. This was also consistent for dogs with CE who 
had a significant increase in the abundance of E. coli compared to healthy control dogs. 
Finally, while the abundance of Bacteroidetes was significantly increased in dogs with 
CE, the abundance of  Firmicutes was decreased in dogs with AHD when compared to 










HYPOTHESIS AND OBJECTIVES 
The hypothesis of this study was that differences exist between the fecal 
microbiome and fecal concentrations of short-chain-fatty-acids (SCFA) between healthy 
dogs, dogs with acute non-hemorrhagic diarrhea (NHD), and dogs with acute 
hemorrhagic diarrhea (AHD). 
The objectives of this study were to  
(1) evaluate the fecal microbiota in healthy dogs, dogs with NHD, and 
dogs with AHD using 16S rRNA gene sequencing and qPCR 
analysis, 
(2) to predict the fecal metagenome based on the 16S rRNA gene 
data, and 













FECAL MICROBIOME IN DOGS WITH ACUTE DIARRHEA 
 
SUMMARY 
 The aim of this study was to evaluate the fecal microbiota in healthy dogs, dogs 
with acute non-hemorrhagic diarrhea (NHD), and dogs with acute hemorrhagic diarrhea 
(AHD) using 16S rRNA gene sequencing and quantitative real-time Polymerase Chain 
Reaction (qPCR) analysis, to predict the functional content from the 16S rRNA gene 
data, and to measure fecal concentrations of short-chain fatty acids (SCFAs) and 
branched-chain fatty acids (BCFAs). Fecal samples were collected from 13 healthy dogs, 
5 dogs with NHD, and 6 dogs with AHD. For 454-pyrosequencing and qPCR, feces 
from 8 of 13 healthy dogs and all dogs from the diseased groups (n=11) were used. For 
some dogs, there were not enough left-over feces to complete all analyses therefore 
analysis of SCFA and BCFA consisted of fecal samples from 8 of 13 healthy dogs, 3 of 
5 dogs with NHD, and 4 of 6 dogs with AHD.  
Microbial diversity was significantly decreased in dogs with AD compared to 
healthy dogs (Shannon Index: p=0.0022). More specifically when comparing all groups 
(e.g., healthy dogs, dogs with NHD, and dogs with AHD), a Dunn’s post-test revealed a 
significant decrease in microbial diversity in dogs with NHD, compared to healthy dogs 
(Shannon Index: p=0.0208). Fecal microbial communities were significantly different 
between healthy dogs and dogs with AD (ANOSIM; p=0.0040). Furthermore, microbial 
communities were significantly different between healthy dogs and dogs with NHD and 
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dogs with AHD (ANOSIM: p=0.0020 for both). Abundances of sequences belonging to 
the phylum Bacteroidetes were significantly decreased in dogs with AD compared to 
healthy dogs (p=0.0280).  Also, abundances of sequences belonging to the genus 
Faecalibacterium and an unclassified genus within the family Ruminococcaceae were 
both significantly decreased in fecal samples from dogs with AD compared to those 
from healthy dogs (p=0.0319 and 0.0368, respectively). In contrast, sequences belonging 
to the genus Clostridium were significantly increased in dogs with AD compared to 
healthy dogs (p=0.0476). Results from qPCR revealed that the abundance of Blautia spp. 
were significantly decreased in dogs with AD compared to healthy dogs (p=0.0472), 
while the abundance of Clostridium perfringens was significantly increased in dogs with 
AD compared to healthy dogs (p=0.0088). When comparing all groups (e.g., healthy 
dogs, dogs with NHD, and dogs with AHD), a Dunn’s post-test revealed a significant 
increase in sequences belonging to Clostridium perfringens in dogs with AHD compared 
to healthy dogs (p<0.05). Proportionally, propionic acid was significantly decreased in 
the feces from dogs with AD compared to those from healthy dogs (p=0.0033). In 
contrast, the proportion of fecal butyric acid was significantly increased in dogs with AD 
compared to healthy dogs (p=0.0048). There were no significant differences observed in 
the functional gene content among all dogs after correcting for multiple comparisons.  
In conclusion, differences in individual bacterial populations and bacterial 
communities were identified between healthy dogs and dogs with acute diarrhea. Fecal 
SCFA concentrations were also different between healthy dogs and dogs with acute 
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diarrhea. Further studies are warranted to evaluate the microbiome in dogs with acute 
diarrhea and evaluate treatment modalities that restore microbial balance. 
 
INTRODUCTION 
 Recent molecular studies have greatly increased our knowledge concerning the 
microbiota harbored in the GIT of dogs, mice, and humans [4,22,42,55]. It has been 
suggested that the total microbial load in the intestinal tract is somewhere between 1012-
1014  organisms, which is approximately 10 times the number of host cells. Studies have 
confirmed that the vast number of microbes that make up the GIT microbiota are a 
necessity in host health, as they play an important role in stimulating the immune 
system, development of gut structure, aiding in the defense against pathogens, and 
providing nutritional benefit to the host (e.g., production of SCFAs) [29,56-60]. 
However, the microbiota has also been implicated in the pathogenesis of certain GIT 
disorders, and must be studied intensely to understand their relationships with the host 
[29]. 
 It has been suggested that in acute episodes of diarrhea the intestinal microbiota 
(e.g., enterotoxigenic C.  perfringens, Salmonella, viruses, and parasites) play a key role 
in pathogenesis of this condition. Other GI disorders (e.g., chronic diarrhea) may also be 
subject to these pathogenic bacteria [54,61,62]. There is limited information from 
molecular studies describing the fecal microbiota in dogs with acute diarrhea and of 
those available, results have varied. Fluorescent in situ hybridization (FISH) probes were 
used in one study and found that Bacteroides cell counts were significantly increased in 
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Beagle dogs that had chronic diarrhea [53]. A study in the feces from dogs with 
unspecified diarrhea used 454-pyrosequencing of the cpn60 gene and found a 
significantly decreased proportion of Bacteroidetes [63]. Another study in dogs with 
episodes of diarrhea revealed increased abundances of Clostridium perfringens, 
Enterococcus faecalis, and E. faecium using terminal restriction fragment length 
polymorphism (T-RFLP) analysis and qPCR [56]. One study specifically enrolled dogs 
with acute hemorrhagic diarrhea and dogs with active and therapeutically controlled 
idiopathic IBD. Results from 454-pyrosequencing revealed that dogs with acute 
hemorrhagic diarrhea had significant decreases in Blautia spp. and Ruminococcaceae, 
which are both SCFA producers [54]. These studies are indicative of a fecal dysbiosis 
that is present in dogs with GI disease. However, high-throughput sequencing studies in 
dogs with well-defined disease phenotypes are limited [54]. 
 Studies in humans that focus on GI disease have revealed bacterial shifts that 
significantly reduce the amount of SCFA producing bacteria [64,65].  SCFA producing 
bacteria in one study (e.g.,  Ruminococcus spp., Faecalibacterium spp., Dorea spp., and 
Turicibacter spp.) were found to predominate in the ileum and colon [5].  A decreased 
diversity of Clostridium clusters XIVa and IV (i.e., Ruminococcaceae, Faecalibacterium 
prausnitzii, and C. coccoides subgroups) in IBD patients may indicate that these SCFA 
producing bacteria are important in the maintenance of GI health [29,64,65]. 
Fermentation of dietary substrates such as starch, fiber, cellulose, pectin, and fructans by 
bacteria produce SCFAs, which are a preferred energy source for colonocytes and 
critical in metabolism and epithelial cell growth [66,67]. 
 20 
 
 Recent studies have provided strong data concerning the bacterial phylogeny 
based on 16S rRNA gene surveys. However, these studies still do not provide any 
information pertaining to function. A metagenomics approach could be advantageous as 
it provides data about community structure [68,69]. In one study fecal samples from 
healthy dogs were collected and a metagenomics approach was used to characterize the 
effects of supplemental dietary fiber.  The most represented functional categories among 
the sample population were carbohydrates, protein metabolism, cell wall and capsule, 
cofactors, vitamins, prosthetic groups and pigments, DNA metabolism, RNA 
metabolism, amino acids/derivatives, and virulence factors [69]. Although brief 
overviews of metagenomic studies have been provided, more studies are required to 
characterize the metagenome in healthy dogs and dogs with GI disease. 
 Given the progress of these inter-related fields our aim was to: further evaluate 
the fecal microbiota in healthy dogs, dogs with acute non-hemorrhagic diarrhea (NHD), 
and dogs with acute hemorrhagic diarrhea (AHD) using 16S rRNA gene sequencing and 
qPCR analysis, analyze functional gene content based on the 16S rRNA gene data, and 
measure fecal concentrations of SCFAs and BCFAs. 
 
MATERIALS AND METHODS 
Animal enrollment and sample collection. Naturally passed fecal samples were 
obtained from healthy dogs as well as dogs with acute diarrhea (AD); dogs with AD 
were further classified as dogs with acute non-hemorrhagic diarrhea (NHD) or dogs with 





Table 1. Signalment for dogs enrolled in the study. 
       
Animal ID Age (years) Breed 
Sex and sexual 
status 
H1 3 Labrador MN 
H2 7 Boston terrier mix MN 
H3 9 Labrador FS 
H4 5 German shepherd FS 
H5 3 Australian Kelpie F 
H6 1 Labrador mix F 
H7 10 Weimaraner MN 
H8 8 Miniature schnauzer FS 
H9 12 Miniature schnauzer FS 
H10 5 Boxer mix MN 
H11 3 Australian shepherd FS 
H12 1 Maltipoo FS 
H13 7 Boston terrier MN 
NHD1 1 Husky/shepherd mix FS 
NHD2 1 Miniature pinscher F 
NHD3 12 American collie FS 
NHD4 1 Brittany spaniel M 
NHD5 6 Basset hound FS 
AHD1 7 Labrador MN 
AHD2 1 Brittany spaniel MN 
AHD3 5 Bulldog MN 
AHD4 3 Shetland sheepdog FS 
AHD5 2 Dachshund F 
AHD6 10 American Pit Bull terrier MN 
H = Healthy dogs; NHD = dogs with acute non-hemorrhagic diarrhea; AHD = dogs 
with acute hemorrhagic diarrhea. 
M = intact male; MN = male neutered; F = intact female; FS = female spayed. 
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collection, transferred within a few hours to a -80º C freezer, and stored frozen until 
processing for DNA extraction. The collection of fecal samples was approved by the 
Texas A&M University Institutional Animal Care and Use Committee (IACUC): 
Protocol Number; 2012-101. 
The control group consisted of 13 healthy dogs (Table 1). Since there was not 
enough feces available from each individual healthy dog for all analyses, fecal material 
from healthy animals with IDs H1 to H8 were used for 454-pyrosequencing and qPCR 
analysis, while feces from healthy animals with IDs H4, H7, and H8 to H13 were used in 
SCFA analysis, resulting in an n=8 for the healthy control group. All dogs were privately 
owned, lived in various home environments, and were fed a variety of commercial diets. 
None of the dogs had a history of gastrointestinal signs or administration of antibiotics 
for at least a month prior to collection of fecal samples. All healthy dogs lived in Texas, 
USA. 
The diseased group consisted of 11 pet dogs with AD (5 NHD and 6 AHD) that 
presented to the Veterinary Medical Teaching Hospital at Texas A&M University with 
acute, non-hemorrhagic or hemorrhagic diarrhea (duration of diarrhea <3 days) (Table 
1). Unfortunately, there was not enough left-over feces available from each individual 
dog to analyze SCFA/BCFA concentrations, therefore, 3 of 5 (animal IDs: NHD3 to 
NHD5) dogs with NHD and 4 of 6 (animal IDs: AHD1 to AHD2 and AHD4 to AHD6) 
dogs with AHD were used. None of the dogs had a previous history of GI signs or had 
received antibiotics within the previous three months. Diagnostic evaluation included a 
complete blood count (CBC), serum chemistry profiles (SIRRUS® Clinical Chemistry 
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Analyzer), serum concentrations of canine trypsin-like immunoreactivity (cTLI) 
concentration, serum concentrations of canine pancreatic lipase immunocreactivity 
(cPLI), serum concentrations of cobalamin and folate (Immulite 2000 Vitamin B12, 
Folic Acid, Siemens Medical Solutions Diagnostics), and serum concentrations of C-
reactive protein (CRP; Phase ™Range Canine C-reactive Protein Assay, Tridelta 
Development Ltd), and urine analysis.  
 Summary statistics of both healthy and diseased groups of dogs are displayed in 
Table 2. 
DNA isolation. Approximately 100 mg of feces was aliquoted into a sterile 1.7 
ml tube (Microtube, Sarstedt AG & Co, Nümbrecht, Germany) containing 150 µl of 0.1 
mm zirconia-silica beads and 100 µl of 0.5 mm zirconia-silica beads (BioSpec Products 
Inc., Barlesville, OK, USA).  The DNA was extracted using the ZR fecal DNA Mini 
Prep kit (Zymo Research, Irvine CA, USA). A volume of 750 µl of lysis buffer was 
added to each sample. Samples were then homogenized (FastPrep-24, MP Biomedicals, 
USA) for a duration of 1 minute at a speed of 4 m/s. Tubes then underwent 
centrifugation at 10,000 x g for 1 minute and the remaining DNA extraction was carried 
out as recommended by the manufacturer. For downstream PCR analysis the 
concentration of the isolated DNA was measured by a spectrophotometer (NanoDrop 
2000, Thermo Scientific, Wilmington, DE USA) and normalized to 5 ng/μl by adding 










Table 2. Basic summary statistics of all dogs.     
         
 Healthy NHD AHD AD M-W p-value K-W p-value 
Age (years; median, range) 5.0, 1.0-10.0 1.0, 1.0-12.0 4.0, 1.0-10.0 3.0, 1.0-12.0 0.4934 0.7774 
Weight (kg; median, range) 20.4, 5.5-31.8 20.9, 7.3-31.6 22.5, 5.0-44.4 20.9, 5.0-44.4 0.3415 0.5703 
Sex (female/male) 8/5 4/1 2/4 6/5 *F1=0.4314 *F2=0.3044 
NHD = dogs with acute non-hemorrhagic diarrhea; AHD = dogs with acute hemorrhagic diarrhea; AD = both groups combined 
(NHD and AHD). 
M-W p-value = P-value from Mann-Whitney U test comparing Healthy vs. AD. 
K-W p-value = P-value from Kruskal-Wallis test comparing Healthy vs. NHD vs. AHD. 
*F1 = P-value from Fisher’s exact test comparing proportions for Healthy vs. AD. 
*F2 = P-value from Fisher’s exact test comparing proportions for Healthy vs. NHD vs. AHD. 
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454-Pyrosequencing. Bacterial tag-encoded FLX-titanium amplicon 
pyrosequencing (bTEFAP) was performed targeting the V4-V6 region of the 16S rRNA 
gene using forward and reverse primers: 530F (5’-GTGCCAGCMGCNGCGG-3’) and 
1100R (5’-GGGTTNCGNTCGTTG-3’), respectively [70]. Raw sequence data were 
screened, trimmed, de-noised, filtered, and depleted of chimeras using the QIIME 
(Quantitative Insights Into Microbial Ecology) open-source pipeline [35]. Operational 
taxonomic units (OTUs) were assigned based on at least 97% sequence similarity using 
QIIME. 
Quantitative PCR (qPCR) assays. To validate pyrosequencing results and to 
evaluate bacterial groups that are typically present at very low abundance or not detected 
in sequencing data, qPCR was used. A panel of seven qPCR assays was performed for 
specific bacterial groups: Lactobacillus spp., Bifidobacterium spp., Escherichia coli, 
Clostridium perfringens, Faecalibacterium spp., and Veillonellaceae (Table 3). 
Quantitative PCR was also used to detect the coenzyme A-activated form of butyric 
acid. A commercially available qPCR thermal cycler (CFX96TM, Bio-Rad Laboratories, 
CA, USA) was used to execute protocols customized for individual qPCR assays (Table 
3 summarizes qPCR assay protocols used). Data was expressed as log amount of DNA 
per 10 ng of isolated total DNA.  
Quantitative PCR reactions were performed using two reaction chemistries. For a 
subset of assays (Table 3) SYBR-green based reaction mixtures were used, with a total 
reaction volume of 10 µl. The final mix contained 5 µl SsoFast™ EvaGreen® supermix 
(Bio-Rad Laboratories, CA, USA), 0.4 µl each of a forward and reverse primer (final 
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concentration: 400 nM), 2.6 µl of high quality PCR water, and 2 µl of normalized DNA 
(final concentration: 5 ng/µl). Conditions for PCR were as follows: initial denaturation at 
98ºC for 2 min, then 40 cycles with denaturation at 98ºC for 3 sec and annealing (see 
Table 3 for specific annealing temperatures) for 3 sec. Post-amplification, a melt curve 
analysis was performed using these conditions: 95ºC for 1 min, 55ºC for 1 min, and 
increasing incremental steps of 0.5ºC for 80 cycles for 5 sec each. All samples were run 
in duplicate fashion. 
TaqMan® based reaction mixtures were used in a total reaction volume of 10 µl. 
The final mix contained 5 µl TaqMan® Fast Universal PCR master mix (Life 
Technologies, NY, USA), 0.4 µl of a forward and reverse primer (final concentration: 
400 nM), 2 µl of high quality PCR water, and 2 µl of normalized DNA (final 
concentration: 5 ng/μl). Conditions for PCR were as follows: initial denaturation at 95ºC 
for 20 sec then 40 cycles with denaturation at 95°C and annealing (see Table 3 for 
specific annealing temperatures) for 3 sec. Post-amplification, a melt curve analysis was 
performed using these conditions: 95ºC for 1 min, 55ºC for 1 min, and increasing 
incremental steps of 0.5ºC for 80 cycles for 5 sec each. All samples were run in duplicate 
fashion. 
Fatty acid analysis. Concentrations of short-chain fatty acids (SCFA; i.e., 
acetate, propionate, and butyrate), and branched chain fatty acids (BCFA; i.e., 
isobutyrate, isovalerate, and valerate) in feces were measured using a stable isotope 
dilution gas chromatography-mass spectrometry (GC-MS) assay as previously described 




Table 3. Oligonucleotide primers/probe used for this study. 
    




F-AGCAGTAGGGAATCTTCCA Lactobacillus  58 [72] 
R-CACCGCTACACATGGAG    
F-TCGCGTCYGGTGTGAAAG Bifidobacterium  60 [73] 
R-CCACATCCAGCRTCCAC    
F-GTTAATACCTTTGCTCATTGA Escherichia coli 55 [73] 
R-ACCAGGGTATCTAATCCTGTT    
F-CGCATAACGTTGAAAGATGG C. perfringens 58 [74] 
R-CCTTGGTAGGCCGTTACCC    
Probe-TCATCATTCAACCAAAGGAGCAATCC    
F-GAAGGCGGCCTACTGGGCAC Faecalibacterium  60 [75] 
R-GTGCAGGCGAGTTGCAGCCT    
F-GGCTHAACCCCRTGAKGGR Veillonellaceae 61 This study 
R-RCCKTGCACCACCTGTYTTC    
F-GCIGAICATTTCACITGGAAYWSITGGCAYATGCCTGC Butyryl-CoA 53 [76] 
R-CTTTGCAATRTCIACRAANGC    
F-TCTGATGTGAAAGGCTGGGGCTTA Blautia  56 [54] 
R-GGCTTAGCCACCCGACACCTA    
F = forward primer; R = reverse primer.    
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1:5 in extraction solution (2 N hydrochloric acid).  After homogenization using a multi-
tube vortexer for 30 min at room temperature, fecal suspensions were centrifuged for 20 
min at 2,100 x g and 4°C. Supernatants were then collected using serum filters 
(Fisherbrand serum filter system, Fisher Scientific Inc, Pittsburgh, Pa). From each 
sample, 500 μl of supernatant were mixed with 10 μl of internal standard (200 mM 
heptadeuterated butyric acid) and extracted using a C18 solid phase extraction column 
(Sep-Pak C18 1 cc Vac Cartridge, Waters Corporation, Milford, MA). Samples were 
derivatized using N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) at 
room temperature for 60 min. A gas chromatographer (Agilent 6890N, Agilent 
Technologies Inc, Santa Clara, CA) coupled with a mass spectrometer (Agilent 5975C, 
Agilent Technologies Inc, Santa Clara, CA) was used for chromatographic separation 
and quantification of the derivatized samples. Separation was achieved using a DB-1ms 
capillary column (Agilent Technologies Inc, Santa Clara, CA). The GC temperature 
program was as follows: 40°C  held for 0.1 min, increased to 70°C by 5°C/min, 70°C 
held for 3.5 min, increased to 160°C by 20°C/min, and finally increased to 280°C for 3 
min by 35°C/min. The total run time was 20.53 min. The mass spectrometer was 
operated in electron impact positive-ion mode with selective ion monitoring at mass-to-
charge ratios (M/Z) of 117 (acetate), 131 (propionate), 145 (butyrate and isobutyrate), 
152 (deuterated butyrate; internal standard), and 159 (valerate and isovalerate). 
Quantification was based on the ratio of the area under the curve of the internal standard 




For determination of fecal dry weight, a 100 mg sample of feces from each 
sample was aliquoted into a sterile 1.7 ml serum tube (Microtube, Sarstedt AG & Co, 
Nümbrecht, Germany). This separate aliquot was weighed and dried at 105°C in an oven 
(Symphony Gravity Convection Oven, VWR) for 24 hours. The percent of dry weight 
was calculated and applied to respective concentrations (measured in µmol/g of dry 
feces for all SCFAs/BCFAs) to calculate total SCFA/BCFA concentrations normalized 
by dry weight.  
Statistical analyses. For sequence analysis, to account for unequal sequencing 
depth across samples and to avoid exclusion of samples with lower number of sequence 
reads, the subsequent analysis was performed on a randomly selected subset of 6,900 
sequences per sample. Differences in microbial communities between healthy dogs, dogs 
with NHD, and dogs with AHD were analyzed using the phylogeny-based unweighted 
UniFrac distance metric, and PCoA plots and rarefaction curves were plotted using 
QIIME [35]. Rarefaction curves and PCoA plots illustrated alpha (e.g., Chao 1, Shannon 
Index, and Observed Species) and beta (microbial community distance matrix) diversity. 
ANOSIM function, or “Analysis of Similarity” from the software package PRIMER 6 
(PRIMER-E Ltd., Luton, UK), was used to determine significant differences in the 
composition of the microbiota between healthy dogs and diseased dogs. To visualize the 
relative abundance of bacterial families for individual fecal samples, heat maps were 
generated in NCSS 2007 (NCSS, Kaysville, Utah). 
 All datasets were tested for normality using the Shapiro-Wilk test (JMP 10, SAS 
software Inc.). Only bacterial taxa that were present in at least 70% of dogs (either 
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healthy or diseased) were included in 454-pyrosequencing data analysis. Because most 
datasets did not meet the assumptions of normal distribution, the differences in the 
proportions of bacterial taxa (defined as percentage of total sequences), qPCR results 
(defined as log DNA), functional groups (defined as relative number of KEGG 
orthologs), and SCFAs and BCFAs (defined as µmol/g of dry feces or percent of total 
SCFAs) between healthy and disease groups were determined using non-parametric 
Kruskal-Wallis tests (healthy dogs vs. dogs with NHD vs. dogs with AHD) or a Mann-
Whitney U test (healthy dogs vs. dogs with acute diarrhea (AD [dogs with NHD and 
dogs with AHD combined]). The resulting p-values of the Kruskal-Wallis tests or Mann-
Whitney U test were corrected for multiple comparisons using the Benjamini & 
Hochberg’s False Discovery Rate (FDR), and an adjusted p<0.05 was considered 
statistically significant [77]. For those groups (e.g. bacterial groups, SCFAs and BCFAs) 
that were still significant after p-value adjustment, a Dunn’s post-test was used to 
determine, which animal phenotype were significantly different from the rest. In addition 
to this, SCFA comparisons were performed using two different approaches, one 
evaluated total SCFA and total BCFA concentrations normalized by dry weight (defined 
as µmol/g of dry feces), the other evaluated specific SCFA concentrations (i.e., acetic 
acid, butyric acid, and propionic acid) as a percent of the total SCFAs.  
Linear discriminant analysis effect size (LEfSe) was performed to elucidate 
statistical and biological significance of the microbiota data obtained from 454-
pyrosequencing. LEfSe is freely available online in the Galaxy workflow framework 
[78,79]. A histogram of the linear discriminant analysis scores was constructed to 
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express bacterial groups differentially abundant between healthy dogs and dogs with 
AD. LEfSe scores can be useful in interpreting the degree of difference in the relative 
abundance between features in the two classes (e.g., healthy dogs and dogs with AD) of 
analyzed microbial communities [80]. 
 454-pyrosequencing of the 16S rRNA gene is a key tool for studying microbial 
communities. However, it does not provide direct evidence of the functional capabilities 
of a bacterial community. For our study, PICRUSt (Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States) was used to perform ancestral 
state reconstruction, along with a weighting method, to make predictions of the gene 
content (with estimates of uncertainty) for all organisms represented in the Greengenes 
phylogenetic tree of 16S gene sequences [81]. Any functional classification scheme can 
be used with PICRUSt; in our study, we used the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) Orthology classification scheme [82]. The number of KEGG 
orthologs belonging to functional categories was normalized among levels 1, 2, and 3 in 
order to evenly represent KEGG orthologs across all groups of dogs. PICRUSt is freely 
available online in the Galaxy workflow framework and can also be used through 
QIIME open-source pipeline [78,79]. 
 
RESULTS 
  Sequence analysis. The analysis pipeline yielded 297,315 quality sequences for 
the 19 samples analyzed (mean ± standard deviation [of all samples] = 9013.7 ± 1203.9). 
To account for unequal sequencing depth across samples and to avoid excluding samples 
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with lower number of sequencing reads, the subsequent analysis was performed on a 
randomly selected subset of 6,900 sequences per sample. Figures 1, 2, and 3 illustrate 
the rarefaction curves for the Chao1 metric (an estimate of true species richness), 
observed species (a count of all unique operational taxonomic units (OTUs)), and 
Shannon Index (describes bacterial diversity by taking into account species richness and 
evenness). The aforementioned diversity measures are summarized in Table 4. The 
Shannon Index was significantly decreased in dogs with AD (mean ± standard deviation 
(SD): 4.0 ± 0.6) relative to healthy dogs (mean ± SD: 4.8 ± 0.4; p=0.0022). The Shannon 
Index was significantly decreased in dogs with NHD (mean ± SD: 4.0 ± 0.2) compared 
to healthy dogs (mean ± SD: 4.8 ± 0.4; p<0.05). No significant differences were seen for 
observed species and Chao 1 across the dog groups.  
The percent of sequences (phylum and genus level) observed in all dogs are 
illustrated in Figure 4 and 5, respectively. Bacterial groups included in the statistical 
analysis are described in Table 5. All bacterial groups (e.g., including bacterial groups 
present with low abundance) regardless of being included in statistical analysis are 
described in Table 6.  Sequences belonging to the phylum Bacteroidetes were 
significantly decreased in dogs with AD compared to healthy dogs (p=0.0280). 
Sequences belonging to the genus Faecalibacterium and an unclassified genus within the 
family Ruminococcaceae were both significantly decreased in dogs with AD compared 
to healthy dogs (p=0.0319 and 0.0368, respectively). Sequences belonging to the genus 
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Table 4. Summary of alpha diversity measures. 
   
 Mean ± SD  
 Healthy AD NHD AHD M-W p-value K-W p-value 
Observed Species  268.1±52.8 201.3±56.7 200.3±48.5 204.6±35.8 0.0519 0.1465 
Shannon Index  4.8a±0.4 4.0±0.6 4.0b±0.2 3.9a,b±0.8 0.0022 0.0085 
Chao1 386.1±80.6 303.6±87.0 291.2±57.7 305.8±109.7 0.3637 0.3300 
NHD = dogs with acute non-hemorrhagic diarrhea; AHD = dogs with acute hemorrhagic diarrhea; AD = both groups 
combined (NHD and AHD). 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs and dogs with AD. 
K-W p-value = P-value from Kruskal-Wallis test comparing healthy dogs, dogs with NHD, and dogs with AHD. 
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Table 5. Relative percentages of bacteria included in statistical analysis at various phylogenetic levels based on pyrosequencing. 
median(min-max) *in percent 






Bacteroidetes 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 0.0280 0.0805 
Firmicutes 60.9(41.3-86.6) 72.2(32.7-99.9) 72.2(32.7-99.9) 71.3(47.5-99.8) 0.7213 0.9918 
Fusobacteria 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 0.0793 0.1915 
Proteobacteria 0.1(0.0-0.3) 0.1(0.0-1.2) 0.1(0.0-1.2) 0.1(0.0-0.2) 0.9596 0.6914 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 0.9008 0.8398 
Class  
Bacilli 2.8(0.1-31.8) 4.6(0.0-77.5) 2.0(0.0-43.3) 10.0(0.0-77.5) 0.9639 0.9360 
Bacteroidia 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 0.0504 0.1449 
Clostridia 54.0(26.2-66.1) 47.2(21.8-74.5) 50.2(30.6-64.8) 44.7(21.8-74.5) 1.0653 0.9097 
Epsilonproteobacteria 0.0(0.0-0.1) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.0(0.0-0.1) 0.9202 1.0712 
Erysipelotrichi 4.2(1.5-19.0) 0.4(0.0-6.7) 0.4(0.0-6.7) 0.6(0.2-3.3) 0.0531 0.1413 
Fusobacteria 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 0.0951 0.2298 
Gammaproteobacteria 0.0(0.0-0.3) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.1) 1.1057 0.9079 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 1.0134 1.2092 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 0.9095 0.9225 
Order  
Bacteroidales 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 0.0728 0.2093 
Campylobacterales 0.0(0.0-0.1) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.0(0.0-0.1) 0.9202 0.8439 
Clostridiales 52.3(25.7-65.7) 46.7(21.7-73.7) 50.1(29.8-63.7) 44.3(21.7-73.7) 0.9131 0.9433 
Coriobacteriales 0.3(0.1-1.8) 0.1(0.0-0.6) 0.0(0.0-0.6) 0.1(0.0-0.4) 0.1464 0.3708 
Enterobacteriales 0.0(0.0-0.1) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.0) 0.9685 0.6302 
Erysipelotrichales 4.2(1.5-19.0) 0.4(0.0-6.7) 0.4(0.0-6.7) 0.6(0.2-3.3) 0.0767 0.2041 
Fusobacteriales 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 0.1030 0.2490 
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Table 5. Continued. 
median(min-max) *in percent 






Lactobacillales 2.2(0.1-31.7) 4.6(0.0-47.4) 0.6(0.0-43.3) 10.0(0.0-47.4) 1.0075 0.8565 
Turicibacterales 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 0.2745 0.5362 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 0.9759 0.8733 
unclass. Clostridia_1 0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 0.0793 0.2327 
unclass. Clostridia_2 0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 0.9801 0.4489 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 0.7507 0.6663 
Family 
Bacteroidaceae 14.2(0.6-32.7) 12.6(0.0-18.9) 9.2(0.0-16.1) 12.7(0.0-18.9) 0.4133 0.1957 
Clostridiaceae 13.2(4.7-16.0) 33.0(1.0-53.9) 33.0(1.0-43.8) 31.8(17.4-53.9) 0.0884 0.2490 
Coprobacillaceae 2.6(0.6-13.7) 0.2(0.0-5.5) 0.2(0.0-5.5) 0.3(0.0-1.6) 0.0910 0.1995 
Coriobacteriaceae 0.3(0.1-1.8) 0.1(0.0-0.6) 0.0(0.0-0.6) 0.1(0.0-0.4) 0.1626 0.1622 
Enterobacteriaceae 0.0(0.0-0.1) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.0) 0.8422 0.5521 
Enterococcaceae 0.0(0.0-0.2) 0.0(0.0-10.2) 0.0(0.0-0.1) 0.0(0.0-10.2) 0.8508 0.4170 
Erysipelotrichaceae 1.9(0.4-5.4) 0.4(0.0-5.8) 0.4(0.0-5.8) 0.4(0.0-1.6) 0.0681 0.1326 
Fusobacteriaceae 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 0.1177 0.6987 
Helicobacteraceae 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8691 0.4144 
Lachnospiraceae 25.8(16.8-39.7) 8.7(1.6-48.8) 8.7(5.6-48.8) 8.4(1.6-32.0) 0.1401 0.4415 
Paraprevotellaceae 2.5(0.0-11.6) 0.0(0.0-7.8) 0.0(0.0-1.3) 1.3(0.0-7.8) 0.2958 0.4590 
Peptococcaceae 0.2(0.0-1.3) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.1) 0.3332 0.5125 
Peptostreptococcaceae 0.3(0.1-5.8) 0.1(0.0-4.8) 0.1(0.0-3.5) 0.1(0.0-4.8) 0.3809 0.1898 
Prevotellaceae 9.5(0.0-25.1) 0.0(0.0-1.7) 0.0(0.0-0.0) 0.0(0.0-1.7) 0.0832 0.4649 
Ruminococcaceae 1.8(0.2-5.7) 0.3(0.0-1.1) 0.7(0.0-1.1) 0.3(0.1-1.1) 0.0797 0.2288 
Streptococcaceae 2.2(0.1-11.6) 0.0(0.0-47.4) 0.0(0.0-43.3) 0.1(0.0-47.4) 0.3330 0.4402 
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Table 5. Continued. 
median(min-max) *in percent 






Succinivibrionaceae 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2701 0.5330 
Turicibacteraceae 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 0.2995 0.1803 
unclass. bacteria  0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 0.9008 0.5402 
unclass. Bacteroidales 0.0(0.0-0.2) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 0.8367 0.5300 
unclass. Clostridia_1  0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 0.0793 0.3235 
unclass. Clostridia_2  0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 0.8019 0.4349 
unclass. Clostridiales 0.1(0.0-0.3) 0.2(0.0-0.3) 0.2(0.1-0.3) 0.2(0.0-0.3) 0.3181 17.4668 
unclass. Firmicutes  0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 0.5255 0.3371 
unclass. Lactobacillales 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.3089 0.8126 
Veillonellaceae 3.0(0.1-21.6) 0.6(0.0-3.9) 0.1(0.0-2.0) 0.9(0.4-3.9) 0.3215 0.2096 
Genus  
Allobaculum 0.6(0.0-1.9) 0.1(0.0-5.7) 0.1(0.0-5.7) 0.1(0.0-0.6) 0.4284 0.6893 
Bacteroides 14.2(0.6-32.7) 12.5(0.0-18.9) 9.2(0.0-16.1) 12.6(0.0-18.9) 0.4530 0.6348 
Blautia 14.0(8.9-25.2) 3.6(0.2-19.8) 5.1(0.9-19.8) 2.7(0.2-17.0) 0.0977 0.2216 
Catenibacterium 0.3(0.0-13.2) 0.1(0.0-1.6) 0.0(0.0-0.9) 0.1(0.0-1.6) 0.2893 0.4440 
Clostridium 13.2(4.7-16.0) 31.2(0.3-53.8) 31.2(0.3-43.8) 31.8(17.2-53.8) 0.0476 0.1428 
Collinsella 0.3(0.1-1.7) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.1(0.0-0.3) 0.1058 0.3058 
Dorea 1.5(0.3-12.6) 2.0(0.2-9.8) 2.4(0.2-9.8) 1.6(0.2-6.3) 0.8286 0.9129 
Enterococcus 0.0(0.0-0.2) 0.0(0.0-9.2) 0.0(0.0-0.1) 0.0(0.0-9.2) 0.8810 0.8815 
Escherichia 0.0(0.0-0.1) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.0) 0.9574 0.7592 
Eubacterium 1.0(0.4-3.8) 0.1(0.0-1.0) 0.1(0.0-0.4) 0.2(0.0-1.0) 0.0504 0.1764 
Faecalibacterium 1.5(0.1-5.4) 0.1(0.0-1.1) 0.0(0.0-1.1) 0.1(0.0-0.9) 0.0319 0.1067 
Helicobacter 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8866 0.8981 
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median(min-max) *in percent 






J2-29 0.8(0.0-2.8) 3.5(0.0-8.2) 4.3(0.0-7.1) 2.9(0.0-8.2) 0.2570 0.4603 
Megamonas 1.9(0.1-20.5) 0.6(0.0-1.9) 0.1(0.0-1.9) 0.9(0.2-1.8) 0.4043 0.3563 
Peptococcus 0.2(0.0-1.3) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.1) 0.3683 0.5052 
Phascolarctobacterium 0.0(0.0-1.3) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 0.1953 0.4377 
Prevotella 9.5(0.0-25.1) 0.0(0.0-1.7) 0.0(0.0-0.0) 0.0(0.0-1.7) 0.0896 0.1872 
[Prevotella] 2.5(0.0-11.6) 0.0(0.0-7.8) 0.0(0.0-0.1) 0.0(0.0-7.8) 0.2358 0.3906 
[Ruminococcus] 2.7(0.7-10.6) 2.8(0.1-15.6) 2.8(0.3-15.6) 2.6(0.1-7.0) 0.8770 0.9044 
Ruminococcus  0.1(0.0-0.2) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.1(0.0-0.3) 0.7934 0.8811 
Slackia 0.0(0.0-0.1) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.7038 0.8714 
Streptococcus 0.3(0.0-1.3) 0.0(0.0-9.7) 0.0(0.0-2.3) 0.0(0.0-9.7) 0.3614 0.5124 
Turicibacter 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 0.2956 0.5272 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 0.9228 0.9041 
unclass. Bacteroidales 0.0(0.0-0.2) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 0.8348 0.6496 
unclass. Clostridia_1  0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 0.1098 0.2506 
unclass. Clostridia_2  0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 0.8142 0.4580 
unclass. Clostridiaceae 0.0(0.0-2.7) 0.0(0.0-1.8) 0.2(0.0-1.8) 0.0(0.0-0.2) 0.8022 0.7486 
unclass. Clostridiales 0.1(0.0-0.3) 0.2(0.0-0.3) 0.2(0.1-0.3) 0.2(0.0-0.3) 0.3854 0.5120 
unclass. Coprobacillaceae 0.7(0.0-2.6) 0.0(0.0-5.4) 0.0(0.0-5.4) 0.0(0.0-0.3) 0.1159 0.3293 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 0.5854 0.6150 
unclass. Fusobacteriaceae_1 0.0(0.0-0.3) 0.0(0.0-0.2) 0.2(0.0-0.2) 0.0(0.0-0.1) 0.9080 0.4429 
unclass. Fusobacteriaceae_2 3.2(0.1-11.8) 12.0(0.0-44.0) 21.9(0.0-44.0) 11.9(0.1-20.6) 0.2534 0.4076 
unclass. Lachnospiraceae_1 4.7(3.2-6.7) 1.6(0.2-3.6) 2.9(0.9-3.6) 1.1(0.2-2.9) 0.0840 0.1470 
unclass. Lachnospiraceae_2 0.4(0.0-0.6) 0.1(0.0-0.3) 0.1(0.1-0.2) 0.0(0.0-0.3) 0.0905 0.2030 
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median(min-max) *in percent 






unclass. Lactobacillales  0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.3629 0.4180 
unclass. Peptostreptococcaceae_1 0.0(0.0-0.0) 0.0(0.0-0.3) 0.0(0.0-0.0) 0.0(0.0-0.3) 0.7815 0.7432 
unclass. Peptostreptococcaceae_2 0.3(0.1-5.7) 0.1(0.0-4.5) 0.1(0.0-3.5) 0.1(0.0-4.5) 0.4253 0.6896 
unclass. Ruminococcaceae_1 0.1(0.0-0.3) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.1) 0.0368 0.1292 
unclass. Ruminococcaceae_2 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.1) 0.1900 0.3964 
unclass. Streptococcaceae 1.8(0.0-10.8) 0.0(0.0-41.0) 0.0(0.0-41.0) 0.0(0.0-37.7) 0.3786 0.6210 
unclass. Veilonellaceae 0.1(0.0-1.1) 0.0(0.0-0.4) 0.0(0.0-0.2) 0.0(0.0-0.4) 0.4113 0.6166 
NHD = dogs with acute non-hemorrhagic diarrhea; AHD = dogs with acute hemorrhagic diarrhea; AD = both groups combined 
(NHD and AHD). 
M-W p-value = P-value for Mann-Whitney U test comparing healthy dogs vs. AD adjusted based on the Benjamini and Hochberg 
False Discovery Rate. 
K-W p-value = P-value for Kruskal-Wallis test comparing healthy dogs vs. NHD vs. AHD adjusted based on the Benjamini and 
Hochberg False Discovery Rate. 
The abbreviation “unclass.” denotes an unclassified taxonomy within respective taxonomic group. Brackets “[]” denote a proposed 







Table 6. Relative percentages of all bacterial groups at the various phylogenetic levels based on 454-pyrosequencing. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Phylum  
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 
Actinobacteria 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Bacteroidetes 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 
Firmicutes 60.9(41.3-86.6) 72.2(32.7-99.9) 72.2(32.7-99.9) 71.3(47.5-99.8) 
Fusobacteria 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 
Proteobacteria 0.1(0.0-0.3) 0.1(0.0-1.2) 0.1(0.0-1.2) 0.1(0.0-0.2) 
Tenericutes 0.0(0.0-0.1) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
Class  
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 
Actinobacteria 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Bacteroidia 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 
Bacilli 2.8(0.1-31.8) 4.6(0.0-77.5) 2.0(0.0-43.3) 10.0(0.0-77.5) 
Clostridia 54.0(26.2-66.1) 47.2(21.8-74.5) 50.2(30.6-64.8) 44.7(21.8-74.5) 
Erysipelotrichi 4.2(1.5-19.0) 0.4(0.0-6.7) 0.4(0.0-6.7) 0.6(0.2-3.3) 
Fusobacteria 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 
Betaproteobacteria 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Epsilonproteobacteria 0.0(0.0-0.1) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.0(0.0-0.1) 
Gammaproteobacteria 0.0(0.0-0.3) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.1) 
Mollicutes 0.0(0.0-0.1) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
Order 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 
Actinomycetales 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Bifidobacteriales 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Order 
Bacteroidales 32.6(12.9-48.4) 15.3(0.0-27.9) 10.5(0.0-16.1) 15.5(0.1-27.9) 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 
unclass. Bacilli 0.0(0.0-0.0) 0.0(0.0-0.9) 0.0(0.0-0.0) 0.0(0.0-0.9) 
Lactobacillales 2.2(0.1-31.7) 4.6(0.0-47.4) 0.6(0.0-43.3) 10.0(0.0-47.4) 
Turicibacterales 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 
unclass. Clostridia_1 0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 
unclass. Clostridia_2 0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 
Clostridiales 52.3(25.7-65.7) 46.7(21.7-73.7) 50.1(29.8-63.7) 44.3(21.7-73.7) 
Coriobacteriales 0.3(0.1-1.8) 0.1(0.0-0.6) 0.0(0.0-0.6) 0.1(0.0-0.4) 
Erysipelotrichales 4.2(1.5-19.0) 0.4(0.0-6.7) 0.4(0.0-6.7) 0.6(0.2-3.3) 
Fusobacteriales 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 
Burkholderiales 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Campylobacterales 0.0(0.0-0.1) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.0(0.0-0.1) 
Aeromonadales 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Enterobacteriales 0.0(0.0-0.1) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.0) 
Pasteurellales 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Pseudomonadales 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Mollicutes 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Anaeroplasmatales 0.0(0.0-0.0) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
RF39 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 
Microbacteriaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Nocardioidaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Bifidobacteriaceae 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Family  
unclass. Bacteroidales 0.0(0.0-0.2) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Bacteroidaceae 14.2(0.6-32.7) 12.6(0.0-18.9) 9.2(0.0-16.1) 12.7(0.0-18.9) 
Porphyromonadaceae 0.0(0.0-0.8) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Prevotellaceae 9.5(0.0-25.1) 0.0(0.0-1.7) 0.0(0.0-0.0) 0.0(0.0-1.7) 
S24-7 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
[Odoribacteraceae] 0.0(0.0-0.3) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
[Paraprevotellaceae] 2.5(0.0-11.6) 0.0(0.0-7.8) 0.0(0.0-1.3) 1.3(0.0-7.8) 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 
unclass. Bacilli 0.0(0.0-0.0) 0.0(0.0-0.9) 0.0(0.0-0.0) 0.0(0.0-0.9) 
unclass. Lactobacillales 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Enterococcaceae 0.0(0.0-0.2) 0.0(0.0-10.2) 0.0(0.0-0.1) 0.0(0.0-10.2) 
Lactobacillaceae 0.0(0.0-25.9) 0.0(0.0-26.7) 0.0(0.0-26.7) 0.0(0.0-15.2) 
Leuconostocaceae 0.0(0.0-0.0) 0.0(0.0-5.4) 0.0(0.0-0.0) 0.0(0.0-5.4) 
Streptococcaceae 2.2(0.1-11.6) 0.0(0.0-47.4) 0.0(0.0-43.3) 0.1(0.0-47.4) 
Turicibacteraceae 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 
unclass. Clostridia_1 0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 
unclass. Clostridia_2 0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 
unclass. Clostridiales 0.1(0.0-0.3) 0.2(0.0-0.3) 0.2(0.1-0.3) 0.2(0.0-0.3) 
Clostridiaceae 13.2(4.7-16.0) 33.0(1.0-53.9) 33.0(1.0-43.8) 31.8(17.4-53.9) 
Lachnospiraceae 25.8(16.8-39.7) 8.7(1.6-48.8) 8.7(5.6-48.8) 8.4(1.6-32.0) 
Peptococcaceae 0.2(0.0-1.3) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.1) 
Peptostreptococcaceae 0.3(0.1-5.8) 0.1(0.0-4.8) 0.1(0.0-3.5) 0.1(0.0-4.8) 
Ruminococcaceae 1.8(0.2-5.7) 0.3(0.0-1.1) 0.7(0.0-1.1) 0.3(0.1-1.1) 
Veillonellaceae 3.0(0.1-21.6) 0.6(0.0-3.9) 0.1(0.0-2.0) 0.9(0.4-3.9) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Family  
Coriobacteriaceae 0.3(0.1-1.8) 0.1(0.0-0.6) 0.0(0.0-0.6) 0.1(0.0-0.4) 
unclass. Erysipelotrichales_1 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Erysipelotrichales_2 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Erysipelotrichaceae 1.9(0.4-5.4) 0.4(0.0-5.8) 0.4(0.0-5.8) 0.4(0.0-1.6) 
[Coprobacillaceae] 2.6(0.6-13.7) 0.2(0.0-5.5) 0.2(0.0-5.5) 0.3(0.0-1.6) 
Fusobacteriaceae 4.5(0.1-12.7) 16.5(0.1-49.5) 23.5(0.1-49.5) 14.2(0.1-24.2) 
Alcaligenaceae 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Campylobacteraceae 0.0(0.0-0.0) 0.0(0.0-0.3) 0.0(0.0-0.3) 0.0(0.0-0.0) 
Helicobacteraceae 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Succinivibrionaceae 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Enterobacteriaceae 0.0(0.0-0.1) 0.0(0.0-1.1) 0.0(0.0-1.1) 0.0(0.0-0.0) 
Pasteurellaceae 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Pseudomonadaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Mollicutes 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Anaeroplasmataceae 0.0(0.0-0.0) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
unclass. RF39 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Genus  
unclass. bacteria 0.2(0.0-0.8) 0.3(0.0-0.4) 0.4(0.0-0.4) 0.3(0.0-0.3) 
Leucobacter 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Nocardioidaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Bifidobacterium 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
unclass. Bacteroidales 0.0(0.0-0.2) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
unclass. Bacteroidaceae 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Bacteroides 14.2(0.6-32.7) 12.5(0.0-18.9) 9.2(0.0-16.1) 12.6(0.0-18.9) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Genus  
Parabacteroides 0.0(0.0-0.8) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Prevotella 9.5(0.0-25.1) 0.0(0.0-1.7) 0.0(0.0-0.0) 0.0(0.0-1.7) 
unclass. S24-7 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
Odoribacter 0.0(0.0-0.3) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. [Paraprevotellaceae] 0.0(0.0-0.1) 0.0(0.0-2.7) 0.0(0.0-1.2) 0.0(0.0-2.7) 
[Prevotella] 2.5(0.0-11.6) 0.0(0.0-7.8) 0.0(0.0-0.1) 0.0(0.0-7.8) 
unclass. Firmicutes 0.2(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.4) 0.1(0.0-0.2) 
unclass. Bacilli 0.0(0.0-0.0) 0.0(0.0-0.9) 0.0(0.0-0.0) 0.0(0.0-0.9) 
unclass. Lactobacillales 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Enterococcaceae 0.0(0.0-0.0) 0.0(0.0-0.9) 0.0(0.0-0.0) 0.0(0.0-0.9) 
Enterococcus 0.0(0.0-0.2) 0.0(0.0-9.2) 0.0(0.0-0.1) 0.0(0.0-9.2) 
unclass. Lactobacillaceae_1 0.0(0.0-0.1) 0.0(0.0-25.7) 0.0(0.0-25.7) 0.0(0.0-14.9) 
unclass. Lactobacillaceae_2 0.0(0.0-0.0) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.0) 
Lactobacillus 0.0(0.0-25.9) 0.0(0.0-0.8) 0.0(0.0-0.8) 0.0(0.0-0.2) 
unclass. Leuconostocaceae 0.0(0.0-0.0) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
Weissella 0.0(0.0-0.0) 0.0(0.0-5.2) 0.0(0.0-0.0) 0.0(0.0-5.2) 
unclass. Streptococcaceae_1 1.8(0.0-10.8) 0.0(0.0-41.0) 0.0(0.0-41.0) 0.0(0.0-37.7) 
unclass. Streptococcaceae_2 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Lactococcus 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Streptococcus 0.3(0.0-1.3) 0.0(0.0-9.7) 0.0(0.0-2.3) 0.0(0.0-9.7) 
Turicibacter 0.0(0.0-2.2) 0.0(0.0-61.1) 0.0(0.0-1.9) 0.0(0.0-61.1) 
unclass. Clostridia_1 0.4(0.1-0.9) 0.1(0.0-0.5) 0.1(0.0-0.5) 0.2(0.0-0.3) 
unclass. Clostridia_2 0.0(0.0-1.1) 0.0(0.0-0.7) 0.1(0.0-0.7) 0.0(0.0-0.0) 
unclass. Clostridiales 0.1(0.0-0.3) 0.2(0.0-0.3) 0.2(0.1-0.3) 0.2(0.0-0.3) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Genus  
unclass. Clostridiaceae_1 0.0(0.0-2.7) 0.0(0.0-1.8) 0.2(0.0-1.8) 0.0(0.0-0.2) 
unclass. Clostridiaceae_2 0.0(0.0-0.0) 0.0(0.0-1.2) 0.0(0.0-1.2) 0.0(0.0-0.0) 
Clostridium 13.2(4.7-16.0) 31.2(0.3-53.8) 31.2(0.3-43.8) 31.8(17.2-53.8) 
Sarcina 0.0(0.0-0.0) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.0) 
unclass. Lachnospiraceae_1 4.7(3.2-6.7) 1.6(0.2-3.6) 2.9(0.9-3.6) 1.1(0.2-2.9) 
unclass. Lachnospiraceae_2 0.4(0.0-0.6) 0.1(0.0-0.3) 0.1(0.1-0.2) 0.0(0.0-0.3) 
Blautia 14.0(8.9-25.2) 3.6(0.2-19.8) 5.1(0.9-19.8) 2.7(0.2-17.0) 
Coprococcus 0.0(0.0-1.7) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Dorea 1.5(0.3-12.6) 2.0(0.2-9.8) 2.4(0.2-9.8) 1.6(0.2-6.3) 
Roseburia 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
[Ruminococcus] 2.7(0.7-10.6) 2.8(0.1-15.6) 2.8(0.3-15.6) 2.6(0.1-7.0) 
Peptococcus 0.2(0.0-1.3) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.1) 
unclass. Peptostreptococcaceae_1 0.0(0.0-0.0) 0.0(0.0-0.3) 0.0(0.0-0.0) 0.0(0.0-0.3) 
unclass. Peptostreptococcaceae_2 0.3(0.1-5.7) 0.1(0.0-4.5) 0.1(0.0-3.5) 0.1(0.0-4.5) 
unclass. Ruminococcaceae_1 0.1(0.0-0.3) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.1) 
unclass. Ruminococcaceae_2 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.1) 
Faecalibacterium 1.5(0.1-5.4) 0.1(0.0-1.1) 0.0(0.0-1.1) 0.1(0.0-0.9) 
Oscillospira 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Ruminococcus 0.1(0.0-0.2) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.1(0.0-0.3) 
unclass. Veilonellaceae 0.1(0.0-1.1) 0.0(0.0-0.4) 0.0(0.0-0.2) 0.0(0.0-0.4) 
Dialister 0.0(0.0-0.0) 0.0(0.0-0.4) 0.0(0.0-0.0) 0.0(0.0-0.4) 
Megamonas 1.9(0.1-20.5) 0.6(0.0-1.9) 0.1(0.0-1.9) 0.9(0.2-1.8) 
Megasphaera 0.0(0.0-0.0) 0.0(0.0-1.4) 0.0(0.0-0.0) 0.0(0.0-1.4) 
Phascolarctobacterium 0.0(0.0-1.3) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Genus  
Collinsella 0.3(0.1-1.7) 0.0(0.0-0.4) 0.0(0.0-0.4) 0.1(0.0-0.3) 
Slackia 0.0(0.0-0.1) 0.0(0.0-0.2) 0.0(0.0-0.2) 0.0(0.0-0.2) 
unclass. Erysipelotrichales_1 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Erysipelotrichales_2 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Erysipelotrichaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Allobaculum 0.6(0.0-1.9) 0.1(0.0-5.7) 0.1(0.0-5.7) 0.1(0.0-0.6) 
Bulleidia 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
[Eubacterium] 1.0(0.4-3.8) 0.1(0.0-1.0) 0.1(0.0-0.4) 0.2(0.0-1.0) 
unclass. [Coprobacillaceae]_1 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.0) 
unclass. [Coprobacillaceae]_2 0.7(0.0-2.6) 0.0(0.0-5.4) 0.0(0.0-5.4) 0.0(0.0-0.3) 
Catenibacterium 0.3(0.0-13.2) 0.1(0.0-1.6) 0.0(0.0-0.9) 0.1(0.0-1.6) 
Coprobacillus 0.0(0.0-0.6) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.0) 
unclass. Fusobacteriaceae_1 0.0(0.0-0.3) 0.0(0.0-0.2) 0.2(0.0-0.2) 0.0(0.0-0.1) 
unclass. Fusobacteriaceae_2 3.2(0.1-11.8) 12.0(0.0-44.0) 21.9(0.0-44.0) 11.9(0.1-20.6) 
J2-30 0.8(0.0-2.8) 3.5(0.0-8.2) 4.3(0.0-7.1) 2.9(0.0-8.2) 
Sutterella 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
Campylobacter 0.0(0.0-0.0) 0.0(0.0-0.3) 0.0(0.0-0.3) 0.0(0.0-0.0) 
Helicobacter 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.1) 
unclass. Succinivibrionaceae 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Enterobacteriaceae 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Erwinia 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.1) 0.0(0.0-0.0) 
Escherichia 0.0(0.0-0.1) 0.0(0.0-0.5) 0.0(0.0-0.5) 0.0(0.0-0.0) 
Providencia 0.0(0.0-0.0) 0.0(0.0-0.6) 0.0(0.0-0.6) 0.0(0.0-0.0) 
unclass. Pasteurellaceae 0.0(0.0-0.0) 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.1) 
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Table 6. Continued. 
     
 median(min-max) *in percent 
Taxa Healthy AD NHD AHD 
Genus  
Azomonas 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
unclass. Mollicutes 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
Anaeroplasma 0.0(0.0-0.0) 0.0(0.0-0.2) 0.0(0.0-0.0) 0.0(0.0-0.2) 
unclass. RF39 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0(0.0-0.0) 
NHD = dogs with acute non-hemorrhagic diarrhea; AHD = dogs with acute hemorrhagic diarrhea; AD = both groups 
combined (NHD and AHD). 
The abbreviation “unclass.” denotes an unclassified taxonomy within respective taxonomic group. Brackets “[]” denote a 
proposed taxonomy that has not yet been verified. 
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Quantitative PCR. Quantitative PCR data are illustrated in Figure 6 and 
summarized in Table 7. Blautia spp. were significantly decreased in dogs with AD (log 
DNA median [range]: 9.8 [7.9-10.5]) compared to healthy dogs (log DNA median 
[range]: 10.5 [8.7-10.6]; p=0.0472). The abundance of Clostridium perfringens was 
significantly increased in dogs with AD (log DNA median [range]: 7 [5.8-7.5]) 
compared to healthy dogs (log DNA median [range]: 4.6 [3-6.1]; p=0.0088). The 
abundance of Clostridium perfringens was also significantly increased in dogs with 
AHD (log DNA median [range]: 7.1 [6.9-7.4]) compared to healthy dogs (log DNA 
median [range]: 4.6 [3-6.1]; Dunn’s post-test, p<0.05). However, no statistical 
significance could be identified between animal groups for the abundance of the 
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Table 7. Summary statistics of qPCR results. 
    
 median (range) *log DNA   
Bacterial Groups Healthy AD NHD AHD M-W p-value K-W p-value 
Bifidobacterium spp. 4.3(3.2-4.9) 4.9(4.2-6.6) 4.7(4.2-5.3) 5.0(4.3-6.6) 0.1149 0.1701 
Lactobacillus spp. 5.0(3.7-8.5) 4.9(3.7-8.8) 4.4(3.7-8.8) 6.5(3.7-8.1) 0.8683 0.5371 
E. coli 6.7(3.3-7.7) 7.3(6.7-8.4) 7.5(7.0-8.4) 7.2(6.7-7.8) 0.1516 0.3754 
Clostridium perfringens 4.6a (3.0-6.1) 7.0(5.8-7.5) 6.2a,b(5.8-7.5) 7.1b(6.9-7.4) 0.0088 0.0272 
Faecalibacterium spp. 6.7(5.6-7.6) 6.4(4.2-7.1) 6.6(4.2-7.1) 6.2(5.2-6.9) 0.2642 0.5069 
Blautia spp. 10.5(8.7-10.6) 9.8(7.9-10.5) 10.1(9.6-10.5) 9.4(7.9-10.3) 0.0472 0.0836 
Veilonellaceae 9.1(8.8-10.1) 8.8(0.9-9.4) 8.8(0.9-9.4) 8.9(7.9-9.3) 0.1432 0.4072 
Butyryl CoA 5.1(4.8-6.1) 4.8(3.9-5.4) 4.8(3.9-5.4) 4.9(3.9-5.3) 0.1718 0.3409 
NHD = dogs with acute non-hemorrhagic Diarrhea; AHD = dogs with acute hemorrhagic diarrhea; AD = both groups combined 
(NHD and AHD). 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs vs. AD adjusted based on the Benjamini and Hochberg 
False Discovery Rate. 
K-W p-value = P-value from Kruskal-Wallis test comparing healthy dogs vs. NHD vs. AHD adjusted based on the Benjamini and 
Hochberg False Discovery Rate. 
Medians not sharing a common superscript are significantly different (p<0.05 based on Dunn’s post-test). 
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Microbial communities. PCoA plots (Figure 7) based on unweighted Unifrac 
distances were constructed to compare groups of dogs, and showed significant 
differences between healthy dogs and dogs with AD (ANOSIM; healthy dogs vs. dogs 
with AD, p = 0.0040). Furthermore, dogs with NHD and dogs with AHD differed 
significantly from healthy dogs (ANOSIM; dogs with NHD and dogs with AHD vs. 
healthy dogs, p = 0.0020 for both). 
 Linear Discriminant Analysis Effect Size (LEfSe). LEfse is an algorithm for 
high-dimensional biomarker discovery and is an explanation that identifies genomic 
features (genes, pathways, or taxa) characterizing the differences between two or more 
biological conditions (e.g., healthy dogs and dogs with acute diarrhea). LEfSe 
emphasizes both statistical significance and biological relevance, allowing the 
identification of differentially abundant bacterial groups that are also consistent with 
biologically meaningful categories. Clostridium spp. were discovered as high-
dimensional biomarkers for explaining effects in dogs with AD.  In contrast, Prevotella 
spp., Blautia spp., Faecalibacterium spp., Eubacterium spp., an unclassified genus 
within the families Ruminococcaceae, Lachnospiraceae, Clostridia, Ruminococcaceae, 
and Coprobacillaceae were discovered as high-dimensional biomarkers for explaining 
effects in healthy dogs (Figure 8). 
Heat-map illustrating relative sequence abundances. The results in Figure 9 
illustrate a decrease in predominant bacterial groups (e.g., Faecalibacterium and an 
unclassified genus in Ruminococcaceae) and increase in sequences belonging to 
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Functional gene categories. The functional gene content of the fecal 
microbiome was predicted from the 16S rRNA data using the online software 
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt), and compared between healthy dogs and dogs with AD (Table 8, 9, and 10). 
Figure 10 shows a comparison of taxonomic phyla (Figure 10A) and functional gene 
category (Figure 10B) variations in the canine fecal microbiome. The area chart in 
Figure 10B revealed a generally consistent number of KEGG orthologs belonging to 
functional gene categories across all dogs. There were no significant differences in the 
number of KEGG orthologs belonging to functional gene categories at all levels (e.g., 1, 
2, and 3) among all groups of dogs after correcting for multiple comparisons using the 
Benjamini and Hochberg False Discovery Rate. 
SCFA. There were no significant differences in total SCFA or BCFA 
concentrations (µmol/g of dry feces) observed between groups of dogs (Figure 11). 
Summary statistics for these results are shown in Table 11. 
In a separate analysis, butyric acid, acetic acid, and propionic acid were each 
expressed as a percentage of the total amount of fecal SCFA concentrations (Figure 12). 
The proportion of propionic acid was significantly decreased in dogs with AD (median 
[range]:12% [0-25%]) compared to healthy dogs (median [range]: 30% [20-44%]; 
p=0.0033).  In contrast, the proportion of butyric acid was significantly increased in dogs 
with AD (median [range]: 12% [8-26%]) compared to healthy dogs (median [range]: 6% 
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Table 8. Relative percentages of KEGG orthologs belonging to functional gene categories at Level 1. 
     
 Median (min-max) *in percent   
Functional gene categories Healthy AD M-W p-value M-W FDR p-value 
Cellular Processes 1.7(1.4-1.8) 1.5(1.3-3.6) 0.4556 0.9112 
Environmental Information Processing 15.3(14.7-16.4) 15.1(12.5-17.1) 0.8364 0.9559 
Genetic Information Processing 19.7(19.1-20.4) 19.8(19.0-22.1) 0.4824 0.7718 
Human Diseases 0.6(0.6-0.7) 0.7(0.4-0.8) 0.5589 0.7452 
Metabolism 49.3(47.5-49.5) 48.7(46.1-49.5) 0.3627 0.9672 
None 0.1(0.0-0.2) 0.1(0.0-0.2) 0.1436 1.0000 
Organismal Systems 0.6(0.5-0.9) 0.6(0.5-0.8) 0.9339 0.9339 
Unclassified 13.2(12.8-13.6) 13.5(12.7-14.0) 0.2306 0.9224 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs and dogs with AD. 




Table 9. Relative percentages of KEGG orthologs belonging to functional gene categories at level 2. 
     
 median (min-max) *in percent 





Cellular Processes | Cell Growth and Death 0.5(0.4-0.9) 0.5(0.5-0.7) 0.8354 0.9659 
Cellular Processes | Cell Motility 0.8(0.6-1.2) 0.9(0.7-2.4) 0.3618 0.8924 
Cellular Processes | Transport and Catabolism 0.2(0.0-0.2) 0.1(0.1-0.2) 0.5238 0.9229 
Environmental Information Processing | Membrane Transport 14.1(13.6-15.0) 13.7(10.9-16.2) 0.3421 0.9041 
Environmental Information Processing | Signal Transduction 1.3(0.9-1.6) 1.2(1.0-1.6) 0.3406 0.9694 
Environmental Information Processing | Signaling Molecules and Interaction 0.1(0.1-0.2) 0.1(0.0-0.2) 0.2956 0.9114 
Genetic Information Processing | Folding, Sorting and Degradation 2.3(2.1-2.6) 2.4(2.2-2.7) 0.1996 1.0000 
Genetic Information Processing | Replication and Repair 9.0(7.9-9.5) 9.0(8.5-10.0) 0.2475 0.9158 
Genetic Information Processing | Transcription 3.1(2.8-3.3) 3.0(2.7-3.3) 0.9340 0.9874 
Genetic Information Processing | Translation 5.9(5.0-6.3) 5.7(5.0-6.2) 0.5905 0.8403 
Human Diseases | Cancers 0.0(0.0-0.2) 0.1(0.0-0.1) 0.5570 0.8960 
Human Diseases | Immune System Diseases 0.0(0.0-0.1) 0.1(0.0-0.1) 0.5833 0.8633 
Human Diseases | Infectious Diseases 0.3(0.2-0.4) 0.3(0.2-0.5) 0.7390 0.9429 
Human Diseases | Metabolic Diseases 0.1(0.0-0.2) 0.1(0.0-0.2) 0.7383 0.9756 
Human Diseases | Neurodegenerative Diseases 0.0(0.0-0.1) 0.0(0.0-0.1) 0.2246 1.0000 
Metabolism | Amino Acid Metabolism 10.0(9.2-10.8) 10.6(9.2-11.8) 0.1485 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites 1.0(0.8-1.4) 1.0(0.8-1.3) 0.2456 1.0000 
Metabolism | Carbohydrate Metabolism 11.6(11.1-13.0) 11.3(10.1-12.7) 0.1863 1.0000 
Metabolism | Energy Metabolism 6.3(5.4-6.8) 5.8(5.4-6.6) 0.2151 1.0000 
Metabolism | Enzyme Families 2.1(1.8-2.3) 2.0(1.7-2.4) 0.4320 0.8880 
Metabolism | Glycan Biosynthesis and Metabolism 1.4(1.1-1.7) 1.3(1.1-1.9) 0.9670 0.9670 
Metabolism | Lipid Metabolism 2.6(2.3-2.9) 2.6(2.1-3.2) 0.7720 0.9521 
Metabolism | Metabolism of Cofactors and Vitamins 4.5(3.6-4.7) 4.3(4.0-4.8) 0.9341 0.9600 








Table 9. Continued. 
     
 median (min-max) *in percent 





Metabolism | Metabolism of Terpenoids and Polyketides 1.6(1.3-1.8) 1.6(1.1-1.8) 0.5076 0.9391 
Metabolism | Nucleotide Metabolism 3.9(3.4-4.6) 3.9(3.5-4.7) 0.6494 0.8899 
Metabolism | Xenobiotics Biodegradation and Metabolism 2.1(1.6-2.3) 2.3(1.8-2.6) 0.0472 1.0000 
Organismal Systems | Digestive System 0.0(0.0-0.0) 0.0(0.0-0.0) 0.5771 0.8897 
Organismal Systems | Endocrine System 0.2(0.2-0.3) 0.2(0.1-0.4) 0.7986 0.9532 
Organismal Systems | Environmental Adaptation 0.2(0.1-0.3) 0.2(0.1-0.2) 0.8671 0.9722 
Organismal Systems | Excretory System 0.0(0.0-0.0) 0.0(0.0-0.1) 0.5351 0.8999 
Organismal Systems | Immune System 0.1(0.0-0.2) 0.1(0.1-0.2) 0.0768 1.0000 
Organismal Systems | Nervous System 0.1(0.1-0.1) 0.1(0.0-0.2) 0.3735 0.8637 
Unclassified | Cellular Processes and Signaling 3.9(3.5-4.4) 4.0(3.6-4.6) 0.3857 0.8395 
Unclassified | Genetic Information Processing 2.4(2.1-3.0) 2.3(2.2-3.1) 0.9013 0.9808 
Unclassified | Metabolism 2.9(2.3-3.2) 2.7(2.2-3.0) 0.2650 0.8914 
Unclassified | Poorly Characterized 4.2(3.9-4.8) 4.3(4.0-4.9) 0.4820 0.9386 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs and dogs with AD. 
M-W FDR p-value=P-value from Mann-Whitney U test that is adjusted based on the Benjamini and Hochberg False Discovery Rate. 
 64 
 
Table 10. Relative percentages of KEGG orthologs belonging to functional gene categories at Level 3. 
  
 median (min-max) *in percent 





Cellular Processes | Cell Growth and Death | Cell cycle - Caulobacter 0.6(0.3-0.9) 0.5(0.4-0.8) 0.4816 0.9767 
Cellular Processes | Cell Motility | Bacterial chemotaxis 0.3(0.2-0.4) 0.2(0.1-0.6) 0.9338 1.0000 
Cellular Processes | Cell Motility | Bacterial motility proteins 0.2(0.0-0.2) 0.2(0.0-1.0) 0.2599 1.0000 
Cellular Processes | Cell Motility | Cytoskeleton proteins 0.4(0.2-0.5) 0.4(0.3-0.6) 0.5337 0.9815 
Cellular Processes | Cell Motility | Flagellar assembly 0.1(0.1-0.2) 0.1(0.0-0.2) 0.7574 1.0000 
Cellular Processes | Transport and Catabolism | Lysosome 4.2(3.4-4.4) 4.3(2.6-4.9) 1.0000 1.0000 
Cellular Processes | Transport and Catabolism | Peroxisome 0.5(0.4-0.6) 0.4(0.2-0.7) 0.1231 1.0000 
Environmental Information Processing | Membrane Transport | ABC transporters 0.4(0.2-2.3) 0.4(0.2-1.3) 0.3421 0.9768 
Environmental Information Processing | Membrane Transport | Bacterial secretion system 0.8(0.7-1.0) 0.9(0.8-1.1) 0.3601 0.9647 
Environmental Information Processing | Membrane Transport | Phosphotransferase system (PTS) 7.9(7.4-8.7) 8.1(6.0-8.9) 0.8685 1.0000 
Environmental Information Processing | Membrane Transport | Secretion system 0.0(0.0-0.1) 0.0(0.0-0.1) 0.3200 1.0000 
Environmental Information Processing | Membrane Transport | Transporters 0.1(0.0-0.2) 0.1(0.0-0.1) 0.9014 1.0000 
Environmental Information Processing | Signal Transduction | MAPK signaling pathway - yeast 1.1(0.7-1.4) 1.1(0.8-1.5) 0.8645 1.0000 
Environmental Information Processing | Signal Transduction | Phosphatidylinositol signaling system 0.1(0.1-0.2) 0.1(0.1-0.2) 1.0000 1.0000 
Environmental Information Processing | Signal Transduction | Two-component system 0.9(0.6-1.1) 0.9(0.7-1.2) 0.8363 1.0000 
Environmental Information Processing | Signaling Molecules and Interaction | Bacterial toxins 0.0(0.0-0.1) 0.0(0.0-0.1) 0.3284 1.0000 
Environmental Information Processing | Signaling Molecules and Interaction | Cellular antigens 0.5(0.4-0.7) 0.5(0.3-0.7) 0.4742 0.9894 
Environmental Information Processing | Signaling Molecules and Interaction | Ion channels 0.1(0.0-0.1) 0.0(0.0-0.1) 0.4835 0.9715 
Genetic Information Processing | Folding, Sorting and Degradation | Chaperones and folding catalysts 0.4(0.2-0.5) 0.5(0.2-0.7) 0.4806 0.9839 
Genetic Information Processing | Folding, Sorting and Degradation | Proteasome 0.2(0.2-0.4) 0.3(0.3-0.5) 0.5528 0.9914 
Genetic Information Processing | Folding, Sorting and Degradation | Protein export 0.5(0.3-0.6) 0.5(0.4-0.6) 0.7394 1.0000 
Genetic Information Processing | Folding, Sorting and Degradation | Protein processing in endoplasmic reticulum 1.5(1.4-1.7) 1.5(1.3-1.9) 0.7353 1.0000 
Genetic Information Processing | Folding, Sorting and Degradation | RNA degradation 3.0(2.7-3.3) 2.8(2.6-3.4) 0.0675 1.0000 
Genetic Information Processing | Folding, Sorting and Degradation | Sulfur relay system 0.7(0.5-0.8) 0.7(0.5-0.8) 0.0079 0.8572 
Genetic Information Processing | Replication and Repair | Base excision repair 1.2(0.9-1.5) 1.3(1.0-1.7) 0.7383 1.0000 
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Table 10. Continued. 
  
 median (min-max) *in percent 





Genetic Information Processing | Replication and Repair | Chromosome 1.0(0.7-1.2) 1.0(0.7-1.2) 0.7095 1.0000 
Genetic Information Processing | Replication and Repair | DNA repair and recombination proteins 0.8(0.7-1.0) 0.8(0.7-1.0) 0.1998 1.0000 
Genetic Information Processing | Replication and Repair | DNA replication 0.4(0.2-0.5) 0.4(0.2-0.5) 1.0000 1.0000 
Genetic Information Processing | Replication and Repair | DNA replication proteins 0.2(0.1-0.2) 0.2(0.0-0.2) 0.3203 0.9929 
Genetic Information Processing | Replication and Repair | Homologous recombination 2.1(1.4-2.3) 2.1(1.7-2.3) 0.7720 1.0000 
Genetic Information Processing | Replication and Repair | Mismatch repair 1.0(0.8-1.2) 1.0(0.9-1.1) 0.6480 1.0000 
Genetic Information Processing | Replication and Repair | Non-homologous end-joining 1.2(1.0-1.5) 1.1(0.8-1.6) 0.2864 1.0000 
Genetic Information Processing | Replication and Repair | Nucleotide excision repair 0.2(0.1-0.2) 0.2(0.0-0.2) 0.1322 1.0000 
Genetic Information Processing | Transcription | Basal transcription factors 2.2(2.0-2.6) 2.3(1.7-2.6) 0.4555 1.0000 
Genetic Information Processing | Transcription | RNA polymerase 1.4(1.1-1.7) 1.3(1.0-1.6) 0.2321 0.9686 
Genetic Information Processing | Transcription | Transcription factors 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8680 1.0000 
Genetic Information Processing | Transcription | Transcription machinery 0.6(0.5-0.7) 0.5(0.4-0.9) 0.8674 1.0000 
Genetic Information Processing | Translation | Aminoacyl-tRNA biosynthesis 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8687 1.0000 
Genetic Information Processing | Translation | Ribosome 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8362 1.0000 
Genetic Information Processing | Translation | Ribosome Biogenesis 0.0(0.0-0.1) 0.0(0.0-0.1) 0.5348 0.9752 
Genetic Information Processing | Translation | Ribosome biogenesis in eukaryotes 0.1(0.0-0.2) 0.1(0.0-0.2) 0.9659 1.0000 
Genetic Information Processing | Translation | RNA transport 0.1(0.1-0.2) 0.1(0.1-0.2) 0.1695 1.0000 
Genetic Information Processing | Translation | Translation factors 0.1(0.0-0.1) 0.1(0.0-0.2) 0.1587 1.0000 
Human Diseases | Cancers | Pathways in cancer 0.0(0.0-0.1) 0.0(0.0-0.1) 0.4552 1.0000 
Human Diseases | Cancers | Prostate cancer 0.0(0.0-0.1) 0.0(0.0-0.1) 0.6601 1.0000 
Human Diseases | Immune System Diseases | Primary immunodeficiency 0.0(0.0-0.1) 0.1(0.0-0.1) 0.5487 0.9922 
Human Diseases | Infectious Diseases | Epithelial cell signaling in Helicobacter pylori infection 1.2(0.9-1.3) 1.1(0.9-1.5) 0.8999 1.0000 
Human Diseases | Infectious Diseases | Pertussis 1.4(1.2-1.6) 1.5(1.3-1.6) 0.2864 1.0000 
Human Diseases | Infectious Diseases | Staphylococcus aureus infection 1.3(1.1-1.5) 1.3(1.2-1.5) 0.7940 1.0000 
Human Diseases | Infectious Diseases | Tuberculosis 0.9(0.6-1.2) 1.0(0.8-1.3) 0.3573 0.9814 
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Table 10. Continued. 
  
 median (min-max) *in percent 





Human Diseases | Infectious Diseases | Vibrio cholerae pathogenic cycle 0.9(0.8-1.0) 0.9(0.7-1.1) 0.5834 1.0000 
Human Diseases | Metabolic Diseases | Type I diabetes mellitus 0.8(0.6-1.0) 0.7(0.5-1.0) 0.8653 1.0000 
Human Diseases | Metabolic Diseases | Type II diabetes mellitus 0.8(0.7-1.0) 0.9(0.7-1.1) 0.4605 0.9702 
Human Diseases | Neurodegenerative Diseases | Alzheimer's disease 0.1(0.0-0.2) 0.1(0.1-0.2) 0.4743 0.9802 
Human Diseases | Neurodegenerative Diseases | Huntington's disease 0.2(0.1-0.3) 0.2(0.1-0.3) 0.8617 1.0000 
Human Diseases | Neurodegenerative Diseases | Parkinson's disease 0.9(0.8-1.2) 0.9(0.7-1.2) 0.4555 1.0000 
Metabolism | Amino Acid Metabolism | Alanine, aspartate and glutamate metabolism 0.1(0.1-0.2) 0.1(0.0-0.2) 0.3192 1.0000 
Metabolism | Amino Acid Metabolism | Amino acid related enzymes 0.5(0.3-0.6) 0.6(0.3-0.7) 0.8683 1.0000 
Metabolism | Amino Acid Metabolism | Arginine and proline metabolism 0.7(0.5-1.0) 0.7(0.6-0.9) 0.4301 1.0000 
Metabolism | Amino Acid Metabolism | Cysteine and methionine metabolism 0.2(0.1-0.2) 0.2(0.1-0.2) 0.2988 0.9975 
Metabolism | Amino Acid Metabolism | Glycine, serine and threonine metabolism 0.1(0.1-0.1) 0.1(0.0-0.2) 0.9011 1.0000 
Metabolism | Amino Acid Metabolism | Histidine metabolism 0.1(0.0-0.1) 0.1(0.0-0.1) 0.2147 1.0000 
Metabolism | Amino Acid Metabolism | Lysine biosynthesis 0.2(0.2-0.3) 0.2(0.1-0.3) 0.1246 1.0000 
Metabolism | Amino Acid Metabolism | Lysine degradation 0.1(0.1-0.2) 0.1(0.0-0.2) 0.7068 1.0000 
Metabolism | Amino Acid Metabolism | Phenylalanine metabolism 0.3(0.2-0.5) 0.2(0.1-0.4) 0.7711 1.0000 
Metabolism | Amino Acid Metabolism | Phenylalanine, tyrosine and tryptophan biosynthesis 0.2(0.1-0.3) 0.2(0.0-0.3) 0.7096 1.0000 
Metabolism | Amino Acid Metabolism | Tryptophan metabolism 0.0(0.0-0.1) 0.0(0.0-0.1) 0.5544 0.9861 
Metabolism | Amino Acid Metabolism | Tyrosine metabolism 1.4(0.9-2.2) 1.3(1.0-1.7) 0.9007 1.0000 
Metabolism | Amino Acid Metabolism | Valine, leucine and isoleucine biosynthesis 0.1(0.0-0.2) 0.1(0.0-0.1) 0.6487 1.0000 
Metabolism | Amino Acid Metabolism | Valine, leucine and isoleucine degradation 0.7(0.5-0.9) 0.7(0.5-0.8) 0.8332 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | beta-Lactam resistance 0.4(0.2-0.6) 0.4(0.3-0.7) 0.1969 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | Butirosin and neomycin biosynthesis 0.5(0.4-0.8) 0.6(0.1-0.8) 0.8649 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | Flavone and flavonol biosynthesis 1.3(1.0-1.8) 1.2(1.0-1.5) 0.4555 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | Isoquinoline alkaloid biosynthesis 0.7(0.6-0.9) 0.7(0.5-0.9) 0.4155 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | Novobiocin biosynthesis 1.3(1.1-1.5) 1.3(1.1-1.6) 0.2227 1.0000 
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Table 10. Continued. 
  
 median (min-max) *in percent 





Metabolism | Biosynthesis of Other Secondary Metabolites | Phenylpropanoid biosynthesis 0.5(0.4-0.7) 0.5(0.4-0.8) 0.1104 0.9982 
Metabolism | Biosynthesis of Other Secondary Metabolites | Stilbenoid, diarylheptanoid and gingerol biosynthesis 0.1(0.0-0.2) 0.1(0.0-0.1) 0.4555 0.9984 
Metabolism | Biosynthesis of Other Secondary Metabolites | Streptomycin biosynthesis 0.6(0.5-0.7) 0.6(0.2-0.7) 0.1712 1.0000 
Metabolism | Biosynthesis of Other Secondary Metabolites | Tropane, piperidine and pyridine alkaloid biosynthesis 1.0(0.9-1.4) 1.2(0.9-1.3) 0.3387 1.0000 
Metabolism | Carbohydrate Metabolism | Amino sugar and nucleotide sugar metabolism 0.5(0.4-0.8) 0.6(0.4-0.8) 0.4322 1.0000 
Metabolism | Carbohydrate Metabolism | Ascorbate and aldarate metabolism 1.1(0.9-1.3) 1.1(0.8-1.3) 0.1027 1.0000 
Metabolism | Carbohydrate Metabolism | Butanoate metabolism 1.2(1.0-1.5) 1.2(0.9-1.3) 0.3597 0.9757 
Metabolism | Carbohydrate Metabolism | C5-Branched dibasic acid metabolism 0.8(0.5-1.0) 0.7(0.6-0.9) 0.6194 1.0000 
Metabolism | Carbohydrate Metabolism | Citrate cycle (TCA cycle) 0.9(0.8-1.2) 1.0(0.7-1.1) 0.4303 1.0000 
Metabolism | Carbohydrate Metabolism | Fructose and mannose metabolism 1.5(1.3-1.9) 1.5(1.2-2.2) 0.1061 1.0000 
Metabolism | Carbohydrate Metabolism | Galactose metabolism 0.6(0.5-0.9) 0.7(0.4-0.8) 0.2300 0.9982 
Metabolism | Carbohydrate Metabolism | Glycolysis / Gluconeogenesis 1.2(0.9-1.5) 1.3(0.8-1.4) 0.2298 1.0000 
Metabolism | Carbohydrate Metabolism | Glyoxylate and dicarboxylate metabolism 0.5(0.4-0.7) 0.4(0.3-0.6) 1.0000 1.0000 
Metabolism | Carbohydrate Metabolism | Inositol phosphate metabolism 0.4(0.2-0.6) 0.4(0.2-0.6) 1.0000 1.0000 
Metabolism | Carbohydrate Metabolism | Pentose and glucuronate interconversions 0.2(0.1-0.4) 0.2(0.1-0.3) 0.2108 1.0000 
Metabolism | Carbohydrate Metabolism | Pentose phosphate pathway 1.9(1.6-2.1) 1.7(1.4-2.1) 0.5332 1.0000 
Metabolism | Carbohydrate Metabolism | Propanoate metabolism 0.2(0.2-0.4) 0.3(0.1-0.5) 0.0961 1.0000 
Metabolism | Carbohydrate Metabolism | Pyruvate metabolism 0.0(0.0-0.1) 0.1(0.0-0.1) 1.0000 1.0000 
Metabolism | Carbohydrate Metabolism | Starch and sucrose metabolism 0.3(0.2-0.4) 0.2(0.1-0.5) 0.4075 1.0000 
Metabolism | Energy Metabolism | Carbon fixation in photosynthetic organisms 0.1(0.0-0.1) 0.1(0.0-0.2) 0.0881 1.0000 
Metabolism | Energy Metabolism | Carbon fixation pathways in prokaryotes 0.1(0.0-0.1) 0.1(0.0-0.2) 0.8360 1.0000 
Metabolism | Energy Metabolism | Methane metabolism 1.0(0.8-1.1) 0.8(0.7-1.2) 0.8360 1.0000 
Metabolism | Energy Metabolism | Nitrogen metabolism 0.1(0.1-0.2) 0.1(0.0-0.2) 0.9670 1.0000 
Metabolism | Energy Metabolism | Oxidative phosphorylation 0.5(0.3-0.7) 0.6(0.3-0.8) 0.7714 1.0000 
Metabolism | Energy Metabolism | Photosynthesis 0.2(0.2-0.4) 0.2(0.1-0.3) 0.1714 1.0000 
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Table 10. Continued. 
  
 median (min-max) *in percent 





Metabolism | Energy Metabolism | Photosynthesis proteins 0.4(0.4-0.7) 0.5(0.3-0.8) 0.9340 1.0000 
Metabolism | Energy Metabolism | Sulfur metabolism 0.5(0.4-0.7) 0.5(0.4-0.6) 0.5323 1.0000 
Metabolism | Enzyme Families | Peptidases 0.1(0.0-0.2) 0.1(0.0-0.2) 0.2308 0.9820 
Metabolism | Enzyme Families | Protein kinases 0.5(0.3-0.7) 0.5(0.3-0.6) 0.3381 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Glycosaminoglycan degradation 0.0(0.0-0.1) 0.0(0.0-0.1) 0.6514 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Glycosphingolipid biosynthesis - ganglio series 0.0(0.0-0.1) 0.1(0.0-0.1) 0.1345 0.9729 
Metabolism | Glycan Biosynthesis and Metabolism | Glycosphingolipid biosynthesis - globo series 0.1(0.0-0.1) 0.1(0.0-0.1) 0.0068 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Glycosyltransferases 0.1(0.1-0.3) 0.1(0.0-0.2) 0.2622 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Lipopolysaccharide biosynthesis 0.4(0.3-0.6) 0.4(0.2-0.5) 0.8171 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Lipopolysaccharide biosynthesis proteins 0.0(0.0-0.0) 0.0(0.0-0.0) 0.7034 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | N-Glycan biosynthesis 0.4(0.4-0.6) 0.4(0.2-0.7) 0.1917 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Other glycan degradation 0.6(0.5-0.6) 0.6(0.4-0.7) 0.5819 1.0000 
Metabolism | Glycan Biosynthesis and Metabolism | Peptidoglycan biosynthesis 0.5(0.4-0.7) 0.6(0.3-0.7) 0.0681 1.0000 
Metabolism | Lipid Metabolism | Arachidonic acid metabolism 1.0(0.7-1.5) 1.2(1.0-1.4) 0.8163 1.0000 
Metabolism | Lipid Metabolism | Biosynthesis of unsaturated fatty acids 0.1(0.0-0.1) 0.1(0.0-0.1) 0.7036 1.0000 
Metabolism | Lipid Metabolism | Ether lipid metabolism 0.2(0.1-0.4) 0.3(0.2-0.5) 0.6695 1.0000 
Metabolism | Lipid Metabolism | Fatty acid biosynthesis 0.5(0.3-0.7) 0.5(0.3-0.7) 0.7091 1.0000 
Metabolism | Lipid Metabolism | Fatty acid metabolism 0.2(0.1-0.2) 0.2(0.1-0.3) 0.9665 1.0000 
Metabolism | Lipid Metabolism | Glycerolipid metabolism 0.2(0.2-0.4) 0.2(0.1-0.4) 0.3402 0.9843 
Metabolism | Lipid Metabolism | Glycerophospholipid metabolism 0.1(0.0-0.2) 0.1(0.1-0.2) 0.8020 1.0000 
Metabolism | Lipid Metabolism | Linoleic acid metabolism 0.1(0.0-0.2) 0.1(0.1-0.3) 0.4012 1.0000 
Metabolism | Lipid Metabolism | Lipid biosynthesis proteins 0.1(0.0-0.2) 0.1(0.1-0.4) 0.4564 0.9710 
Metabolism | Lipid Metabolism | Primary bile acid biosynthesis 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8994 1.0000 
Metabolism | Lipid Metabolism | Secondary bile acid biosynthesis 0.2(0.1-0.3) 0.2(0.2-0.4) 0.1085 1.0000 
Metabolism | Lipid Metabolism | Sphingolipid metabolism 0.1(0.0-0.2) 0.1(0.0-0.1) 0.7977 1.0000 
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Metabolism | Lipid Metabolism | Steroid hormone biosynthesis 0.2(0.2-0.3) 0.2(0.1-0.5) 0.4555 0.9884 
Metabolism | Lipid Metabolism | Synthesis and degradation of ketone bodies 0.1(0.0-0.2) 0.1(0.1-0.2) 0.4045 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Biotin metabolism 0.0(0.0-0.1) 0.0(0.0-0.1) 0.2123 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Folate biosynthesis 0.2(0.0-0.3) 0.2(0.0-0.3) 0.5336 0.9897 
Metabolism | Metabolism of Cofactors and Vitamins | Lipoic acid metabolism 0.1(0.0-0.3) 0.2(0.1-0.3) 1.0000 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Nicotinate and nicotinamide metabolism 0.2(0.1-0.4) 0.2(0.1-0.4) 1.0000 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | One carbon pool by folate 0.5(0.4-0.7) 0.5(0.4-0.7) 0.5559 0.9807 
Metabolism | Metabolism of Cofactors and Vitamins | Pantothenate and CoA biosynthesis 0.2(0.1-0.2) 0.2(0.1-0.3) 0.7401 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Porphyrin and chlorophyll metabolism 0.1(0.0-0.1) 0.0(0.0-0.1) 0.1477 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Retinol metabolism 2.1(1.8-2.5) 2.2(2.0-2.5) 0.3813 0.9969 
Metabolism | Metabolism of Cofactors and Vitamins | Riboflavin metabolism 1.8(1.6-2.3) 1.9(1.6-2.3) 0.0502 1.0000 
Metabolism | Metabolism of Cofactors and Vitamins | Thiamine metabolism 0.2(0.0-0.2) 0.2(0.1-0.2) 0.5072 0.9916 
Metabolism | Metabolism of Cofactors and Vitamins | Ubiquinone and other terpenoid-quinone biosynthesis 0.2(0.1-0.4) 0.3(0.2-0.4) 0.3395 0.9956 
Metabolism | Metabolism of Cofactors and Vitamins | Vitamin B6 metabolism 0.1(0.0-0.2) 0.2(0.1-0.3) 1.0000 1.0000 
Metabolism | Metabolism of Other Amino Acids | beta-Alanine metabolism 0.4(0.2-0.6) 0.4(0.2-0.6) 0.7079 1.0000 
Metabolism | Metabolism of Other Amino Acids | Cyanoamino acid metabolism 0.1(0.0-0.2) 0.1(0.0-0.2) 0.0662 1.0000 
Metabolism | Metabolism of Other Amino Acids | D-Alanine metabolism 0.1(0.0-0.1) 0.1(0.0-0.1) 0.6458 1.0000 
Metabolism | Metabolism of Other Amino Acids | D-Arginine and D-ornithine metabolism 0.4(0.3-0.4) 0.3(0.2-0.4) 0.1033 1.0000 
Metabolism | Metabolism of Other Amino Acids | D-Glutamine and D-glutamate metabolism 0.1(0.0-0.1) 0.0(0.0-0.1) 0.0843 1.0000 
Metabolism | Metabolism of Other Amino Acids | Glutathione metabolism 0.1(0.0-0.2) 0.0(0.0-0.1) 0.6456 1.0000 
Metabolism | Metabolism of Other Amino Acids | Phosphonate and phosphinate metabolism 0.3(0.2-0.4) 0.3(0.2-0.4) 0.0642 1.0000 
Metabolism | Metabolism of Other Amino Acids | Selenocompound metabolism 0.1(0.0-0.2) 0.1(0.1-0.2) 0.1325 0.9915 
Metabolism | Metabolism of Other Amino Acids | Taurine and hypotaurine metabolism 0.1(0.0-0.2) 0.1(0.0-0.2) 0.5015 0.9984 
Metabolism | Metabolism of Terpenoids and Polyketides | Biosynthesis of ansamycins 0.1(0.0-0.2) 0.1(0.0-0.1) 0.8659 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Biosynthesis of siderophore group nonribosomal peptides 0.1(0.0-0.1) 0.1(0.0-0.2) 0.0350 1.0000 
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Metabolism | Metabolism of Terpenoids and Polyketides | Biosynthesis of vancomycin group antibiotics 0.1(0.0-0.2) 0.1(0.0-0.1) 0.9313 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Geraniol degradation 0.0(0.0-0.1) 0.1(0.0-0.1) 0.2864 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Limonene and pinene degradation 0.2(0.1-0.2) 0.2(0.1-0.4) 0.7392 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Polyketide sugar unit biosynthesis 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8672 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Prenyltransferases 0.1(0.0-0.1) 0.0(0.0-0.1) 0.3527 0.9940 
Metabolism | Metabolism of Terpenoids and Polyketides | Terpenoid backbone biosynthesis 0.0(0.0-0.1) 0.0(0.0-0.1) 0.9010 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Tetracycline biosynthesis 0.1(0.1-0.3) 0.1(0.1-0.2) 0.1950 1.0000 
Metabolism | Metabolism of Terpenoids and Polyketides | Zeatin biosynthesis 0.1(0.0-0.2) 0.1(0.0-0.2) 0.6413 1.0000 
Metabolism | Nucleotide Metabolism | Purine metabolism 0.1(0.0-0.1) 0.1(0.0-0.2) 0.5085 0.9852 
Metabolism | Nucleotide Metabolism | Pyrimidine metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.5897 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Aminobenzoate degradation 0.2(0.1-0.2) 0.2(0.1-0.2) 0.5304 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Atrazine degradation 0.4(0.2-0.5) 0.3(0.1-0.5) 0.4502 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Benzoate degradation 1.0(0.9-1.3) 1.1(0.9-1.2) 0.2610 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Bisphenol degradation 0.1(0.1-0.3) 0.2(0.2-0.4) 0.6167 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Caprolactam degradation 0.1(0.1-0.2) 0.2(0.1-0.3) 0.8767 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Chloroalkane and chloroalkene degradation 0.5(0.2-0.6) 0.5(0.3-0.7) 0.8039 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Chlorocyclohexane and chlorobenzene degradation 1.2(1.0-1.5) 1.3(1.0-1.6) 0.2864 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Dioxin degradation 0.7(0.5-0.8) 0.6(0.4-1.0) 0.7694 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Drug metabolism - cytochrome P450 0.8(0.5-1.1) 0.7(0.6-1.0) 0.2237 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Drug metabolism - other enzymes 0.2(0.1-0.4) 0.1(0.1-0.2) 0.0222 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Ethylbenzene degradation 1.0(0.7-1.1) 0.8(0.7-1.1) 0.8662 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Metabolism of xenobiotics by cytochrome P450 0.4(0.3-0.5) 0.3(0.2-0.6) 0.3547 0.9868 
Metabolism | Xenobiotics Biodegradation and Metabolism | Naphthalene degradation 0.0(0.0-0.1) 0.0(0.0-0.1) 0.6770 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Nitrotoluene degradation 0.1(0.1-0.3) 0.2(0.1-0.3) 0.0665 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Polycyclic aromatic hydrocarbon degradation 0.8(0.7-1.0) 0.8(0.5-1.1) 1.0000 1.0000 
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Metabolism | Xenobiotics Biodegradation and Metabolism | Styrene degradation 0.1(0.0-0.2) 0.1(0.0-0.1) 0.6695 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Toluene degradation 0.0(0.0-0.1) 0.1(0.0-0.1) 0.7815 1.0000 
Metabolism | Xenobiotics Biodegradation and Metabolism | Xylene degradation 1.3(1.1-1.6) 1.3(1.0-1.5) 1.0000 1.0000 
Organismal Systems | Digestive System | Bile secretion 1.1(0.8-1.2) 1.0(0.8-1.3) 0.4555 0.9786 
Organismal Systems | Digestive System | Carbohydrate digestion and absorption 3.3(2.7-3.8) 3.2(3.0-3.6) 0.2796 1.0000 
Organismal Systems | Digestive System | Mineral absorption 0.0(0.0-0.1) 0.0(0.0-0.6) 0.8767 1.0000 
Organismal Systems | Endocrine System | Adipocytokine signaling pathway 0.0(0.0-0.1) 0.0(0.0-0.1) 1.0000 1.0000 
Organismal Systems | Endocrine System | Insulin signaling pathway 0.0(0.0-0.0) 0.0(0.0-0.0) 0.8325 1.0000 
Organismal Systems | Endocrine System | PPAR signaling pathway 0.0(0.0-0.0) 0.0(0.0-0.0) 0.8326 1.0000 
Organismal Systems | Endocrine System | Progesterone-mediated oocyte maturation 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0533 1.0000 
Organismal Systems | Environmental Adaptation | Plant-pathogen interaction 0.0(0.0-0.0) 0.0(0.0-0.0) 0.5038 0.9939 
Organismal Systems | Excretory System | Proximal tubule bicarbonate reclamation 0.0(0.0-0.0) 0.0(0.0-0.0) 0.4363 1.0000 
Organismal Systems | Immune System | Antigen processing and presentation 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0857 1.0000 
Organismal Systems | Immune System | NOD-like receptor signaling pathway 0.0(0.0-0.0) 0.0(0.0-0.1) 0.2998 0.9857 
Organismal Systems | Immune System | RIG-I-like receptor signaling pathway 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2864 0.9865 
Organismal Systems | Nervous System | Glutamatergic synapse 0.0(0.0-0.0) 0.0(0.0-0.0) 0.8991 1.0000 
Unclassified | Cellular Processes and Signaling | Cell division 0.0(0.0-0.0) 0.0(0.0-0.0) 0.4487 1.0000 
Unclassified | Cellular Processes and Signaling | Cell motility and secretion 0.0(0.0-0.0) 0.0(0.0-0.1) 0.1443 1.0000 
Unclassified | Cellular Processes and Signaling | Electron transfer carriers 0.0(0.0-0.0) 0.0(0.0-0.1) 0.6843 1.0000 
Unclassified | Cellular Processes and Signaling | Germination 0.0(0.0-0.1) 0.0(0.0-0.1) 0.8267 1.0000 
Unclassified | Cellular Processes and Signaling | Inorganic ion transport and metabolism 0.0(0.0-0.0) 0.0(0.0-0.1) 0.9666 1.0000 
Unclassified | Cellular Processes and Signaling | Membrane and intracellular structural molecules 0.0(0.0-0.0) 0.0(0.0-0.0) 0.1060 1.0000 
Unclassified | Cellular Processes and Signaling | Other ion-coupled transporters 0.0(0.0-0.0) 0.0(0.0-0.0) 0.9011 1.0000 
Unclassified | Cellular Processes and Signaling | Other transporters 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0252 1.0000 




Table 10. Continued. 
  
 median (min-max) *in percent 





Unclassified | Cellular Processes and Signaling | Signal transduction mechanisms 0.0(0.0-0.1) 0.0(0.0-0.2) 0.4552 1.0000 
Unclassified | Cellular Processes and Signaling | Sporulation 0.0(0.0-0.0) 0.0(0.0-0.0) 0.6789 1.0000 
Unclassified | Genetic Information Processing | Protein folding and associated processing 0.0(0.0-0.0) 0.0(0.0-0.0) 0.1706 1.0000 
Unclassified | Genetic Information Processing | Replication, recombination and repair proteins 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2622 1.0000 
Unclassified | Genetic Information Processing | Restriction enzyme 0.0(0.0-0.0) 0.0(0.0-0.0) 0.0084 0.6076 
Unclassified | Genetic Information Processing | Translation proteins 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2131 1.0000 
Unclassified | Metabolism | Amino acid metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.5332 0.9975 
Unclassified | Metabolism | Biosynthesis and biodegradation of secondary metabolites 0.0(0.0-0.0) 0.0(0.0-0.0) 0.9652 1.0000 
Unclassified | Metabolism | Carbohydrate metabolism 0.0(0.0-0.1) 0.0(0.0-0.1) 0.1233 1.0000 
Unclassified | Metabolism | Energy metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.3200 1.0000 
Unclassified | Metabolism | Glycan biosynthesis and metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.8767 1.0000 
Unclassified | Metabolism | Lipid metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.3719 0.9842 
Unclassified | Metabolism | Metabolism of cofactors and vitamins 0.0(0.0-0.1) 0.0(0.0-0.0) 0.0829 1.0000 
Unclassified | Metabolism | Nucleotide metabolism 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2864 0.9711 
Unclassified | Metabolism | Others 0.0(0.0-0.0) 0.0(0.0-0.0) 0.9341 1.0000 
Unclassified | Poorly Characterized | Function unknown 0.0(0.0-0.0) 0.0(0.0-0.0) 0.8355 1.0000 
Unclassified | Poorly Characterized | General function prediction only 0.0(0.0-0.0) 0.0(0.0-0.0) 0.2635 1.0000 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs and dogs with AD. 
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Table 11. SCFA and BCFA concentrations.   
     
 median (range) *µmol/g dry feces  
Healthy AD M-W p-value M-W FDR p-value 
Acetic Acid 186.0(84.9-420.5) 238.8(83.1-700.0) 0.7285 0.7285 
Propionic Acid 98.6(34.2-260.9) 48.7(0.2-109.5) 0.0826 0.1652 
Butyric Acid 17.2(9.4-54.2) 58.2(8.7-285.1) 0.0641 0.1923 
Isobutyric Acid 4.3(2.0-6.8) 3.2(0.0-4.3) 0.1052 0.1578 
Isoveleric Acid 4.6(1.5-6.0) 3.8(0.0-6.2) 0.6431 0.7717 
Valeric Acid 0.4(0.1-2.1) 0.1(0.0-8.3) 0.0321 0.1926 
AD = both groups combined (dogs with acute non-hemorrhagic diarrhea and dogs with acute hemorrhagic diarrhea). 
M-W p-value = P-value from Mann-Whitney U test comparing healthy dogs and dogs with AD. 
M-W FDR p-value = P-value from Mann-Whitney U test that is adjusted based on the Benjamini and Hochberg 
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Table 12.  Proportions of specific SCFAs of the total fecal SCFAs concentration. 
     
 median (range) *in percent 
Healthy AD M-W p-value M-W FDR p-value 
Butyric acid 6.0(4.0-8.0) 12.0(8.0-26.0) 0.0006 0.0048 
Propionic Acid 30.0(20.0-44.0) 12.0(0.0-25.0) 0.0006 0.0033 
Acetic Acid 64.0(51.0-73.0) 71.0(64.0-90.0) 0.0721 0.0636 
Healthy = healthy dogs; AD = both groups combined (NHD and AHD).  
M-W p-value = P-value for Mann-Whitney U test comparing healthy dogs vs. dogs with AD. 





 The mammalian gastrointestinal tract (GIT) harbors a large number of 
prokaryotic organisms, mainly bacteria, which vastly exceed the number of host cells 
[83]. Molecular-based methods have been used previously to describe the intestinal 
microbiota of healthy dogs and have revealed a diverse and complex microbiota 
consisting of several hundred to several thousand phylotypes present in the GIT 
[4,59,60]. Additionally, bacteria are instrumental in the fermentation of carbohydrates 
and the production of SCFAs, which promote gastrointestinal health in the host [84].  
Gastrointestinal disease (e.g., inflammatory bowel disease (IBD)) has been 
characterized by an altered composition of the intestinal microbiota in humans and also 
in dogs [3,59,60,85]. These studies observed a significantly decreased abundance of 
members of Bacteroidetes and Firmicutes and a significantly increased abundance of 
members of Proteobacteria [3,59,60,85].  
Until recently, there have been limited studies that have described the fecal 
microbiota of dogs with acute GI disorders. In addition to this, limited information has 
been available regarding the relationship between phylogenetic differences, endogenous 
metabolites, and functional changes [69]. Therefore, for this study, we evaluated the 
fecal microbiome of healthy dogs, dogs with NHD, and dogs with AHD. We also 
evaluated the concentration of SCFAs and BCFAs. Furthermore, we predicted the 
functional genes of the microbiome based on the 16S rRNA gene data. Rarefaction 
curves (Figures 1, 2, and 3) and alpha diversity measures (Table 4) revealed a significant 
decrease in the Shannon Index for microbial diversity in dogs with AD compared to 
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healthy dogs. Similarly, trends were observed for a decreased number of observed 
species and the Chao1 metric in dogs with AD. However, this did not reach statistical 
significance.  The reason for this could be due to the low number of samples analyzed in 
combination with the large inter-individual variation in microbial populations that was 
observed.  
 Results from this study are in general agreement with recent molecular studies 
that have examined the fecal microbiota of dogs with acute diarrhea. One study that 
investigated bacterial groups in the feces of dogs with acute diarrhea showed a 
significantly increased abundance of Clostridium spp. [56].  This study found that 
sequence percentages of Clostridium spp. were significantly increased in dogs with AD 
compared to healthy dogs (approximately a 2.5 fold increase); qPCR results from our 
study also showed a significant increase in the abundance of Clostridium perfringens in 
dogs with AD compared to healthy dogs  (approximately a 2 log DNA increase). Studies 
in dogs with unspecified diarrhea showed significantly decreased proportions of 
Bacteroidetes compared to healthy dogs [54,63]. Similarly, our results showed 
significantly decreased proportions of Bacteroidetes compared to healthy dogs. 
The 454-pyrosequencing results of this study showed a significant decrease of 
the abundance of Faecalibacterium spp. among dogs with acute diarrhea compared to 
healthy dogs. Studies in humans with IBD showed a decreased abundance of 
Faecalibacterium prausnitzii [86]. Faecalibacterium prausnitzii has been shown to 
secrete anti-inflammatory peptides in in-vitro studies [65]. More broadly, 
Faecalibacterium spp. have recently been suggested to constitute prominent members of 
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the canine GIT [87]. In one study, FISH analysis of fecal samples from healthy dogs 
identified that the Faecalibacterium-Subdoligranulum group comprised 16% of total 
bacterial counts [87].  
SCFAs are well known to play a role in GI health and disease (e.g., colorectal 
cancer) [67]. Studies in humans have shown that colonic bacteria process fermentable 
carbohydrates to SCFAs, mainly acetate, propionate, and butyrate [67]. Phylogenetic 
groups within the phyla Firmicutes and Bacteroidetes (e.g., belonging to Clostridium 
clusters IV and XIVa), through the production of SCFAs, are thought to contribute 
commensal effects by regulation of the immune system and host metabolism (e.g., 
butyrate is known to decrease the permeability of the intestinal epithelial lining by 
increasing the expression of tight junction proteins and reinforcing colonic defense 
barriers by increasing antimicrobial peptide levels and mucin production [88,89]) [90]. 
In this study, the abundance of sequences belonging to Faecalibacterium and an 
unclassified genus within the family Ruminococcaceae were both decreased in dogs with 
AD compared to healthy dogs; qPCR results also showed a significant decrease in the 
abundance of Blautia spp. in dogs with AD compared to healthy dogs. Some of these 
groups are believed to be important producers of SCFAs [54,91,92]. Results from this 
study showed that the second most abundant SCFA in the feces, being propionic acid, 
was significantly decreased in dogs with AD compared to healthy dogs; this may 
correlate with a decrease in the aforementioned SCFA producing bacteria [93]. A study 
in obese humans found that genera like Roseburia spp., Eubacterium rectale (a subgroup 
of Clostridium cluster XIVa species), and Bifidobacterium  (all thought to be butyrate 
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producing bacteria) were decreased as carbohydrate intake decreased and these butyrate 
producing bacteria correlated well with the decline in fecal butyrate [94]; these results 
show that a correlation may exist between SCFA concentrations and SCFA producing 
bacteria in feces. 
In this study, the functional gene content of the microbiome was predicted from 
16S rRNA gene data. Analysis of the relative abundance of broad functional categories 
of genes (e.g., KEGG derived metabolic pathways) revealed a generally consistent 
pattern regardless of the group of dogs (Figure 10B). This consistency is not only due to 
the broad level of functional categories, as broad taxonomic levels (e.g., phylum) 
revealed substantial variation across fecal microbiomes of all groups of dogs. Based on 
data from this study, it appears that a core fecal microbiome exists at the level of shared 
functional genes. The idea of a core microbiome is similar to what has been described in 
the literature in sequenced metagenomes of humans and is mirrored in the predicted gene 
content generated by the online software, Phylogenetic Investigation of Communities by 
Reconstruction of Unobserved States (PICRUSt) [95,96]. Some significant differences 
were identified based on the Mann-Whitney U test prior to correction by the Benjamini 
and Hochberg false discovery rate. Therefore, the following functional categories: 
xenobiotics biodegradation and metabolism, restriction enzymes (unclassified genetic 
information processing), sulfur relay system (genetic information processing: folding, 
sorting and degradation), glycosaminoglycan degradation (metabolism: glycan 
biosynthesis and metabolism), biosynthesis of siderophore group nonribosomal peptides 
(metabolism: metabolism of terpenoids and polyketides), drug metabolism (metabolism: 
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xenobiotics biodegradation and metabolism), and transporters (unclassified: cellular 
processes and signaling) may deserve further investigation. 
As a limitation to this study, only small numbers of animals were enrolled in 
various disease groups and in the healthy group, partly due to cost restrictions. 
Additionally, in some instances, only a limited amount of sample was available; 
therefore some samples could not be included for all analyses. Also, all dogs, while all 
living in Texas, were on different diets and housed in different environments that were 
not controlled. Differing environments may have an effect on GI microbiota.  In 
addition, functional genes were assigned based on the predicted metagenome based of 











CHAPTER III  
CONCLUSIONS 
 Previous studies that have employed sequencing-based methods to describe the 
intestinal microbiota of healthy dogs have shown a highly complex intestinal ecosystem 
[3,4,59,60,97]. GI disease has been intensely studied in dogs and the current literature 
suggests that alterations in the fecal microbiota may play a role in its pathogenesis 
[56,60].  
Results of this study revealed a bacterial dysbiosis in fecal samples of dogs with 
NHD and dogs with AHD. Microbial diversity was significantly decreased amongst dogs 
with AD compared to healthy dogs (e.g., Shannon Index), indicative of an altered GI 
microbiota associated with GI disease. 
The abundance of Bacteroidetes was significantly decreased in dogs with AD 
compared to healthy dogs. Also, the abundance of bacterial groups (e.g., 
Faecalibacterium spp., an unclassified genus within the family Ruminococcaceae, and 
Blautia spp.) that are consistently depleted in mammalian GI disease and considered to 
be important short-chain fatty acid producers were also decreased in dogs with AD. 
These groups may have a significant impact on the luminal concentrations of SCFA. The 
abundances of bacteria associated with SCFA production, were decreased and this may 
correlate with a decrease in fecal propionate.  
Culture-independent 16S rRNA gene-based techniques have greatly expanded 
our understanding of bacterial phylogeny. Up until recently, a metagenomics approach 
has been widely regarded as costly and therefore impractical, and while some studies 
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have taken this approach, the metagenome of feces in dogs remains largely unstudied. 
Our study observed a core microbiome at the level of shared functional genes. 
Future studies should further correlate metagenomics and the functional gene 
content in dogs with acute diarrhea. A more in depth look at metabolites in dogs with 
acute diarrhea also deserves more attention to begin to understand pathways that are up- 
or down-regulated in the dogs with acute diarrhea. Also, SCFA concentrations and their 
relation to bacteria which produce SCFA should be analyzed in respect to their 
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